CN110294742A - And ring class ASK1 inhibitor and its application - Google Patents
And ring class ASK1 inhibitor and its application Download PDFInfo
- Publication number
- CN110294742A CN110294742A CN201810790218.XA CN201810790218A CN110294742A CN 110294742 A CN110294742 A CN 110294742A CN 201810790218 A CN201810790218 A CN 201810790218A CN 110294742 A CN110294742 A CN 110294742A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- membered
- alkoxy
- amino
- radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940127254 ASK1 inhibitor Drugs 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 196
- 238000002360 preparation method Methods 0.000 claims abstract description 132
- 150000002148 esters Chemical class 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 claims abstract description 24
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 claims abstract description 23
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 9
- -1 C2-10Alkenyl radical Chemical class 0.000 claims description 343
- 229910052736 halogen Inorganic materials 0.000 claims description 99
- 125000000623 heterocyclic group Chemical group 0.000 claims description 99
- 150000003254 radicals Chemical class 0.000 claims description 90
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 87
- 150000002367 halogens Chemical class 0.000 claims description 82
- 125000005843 halogen group Chemical group 0.000 claims description 79
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 239000001257 hydrogen Substances 0.000 claims description 50
- 125000001072 heteroaryl group Chemical group 0.000 claims description 42
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 40
- 150000002431 hydrogen Chemical class 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 34
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 29
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 24
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 23
- 238000006467 substitution reaction Methods 0.000 claims description 23
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 17
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000002393 azetidinyl group Chemical group 0.000 claims description 16
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 16
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 16
- 125000003566 oxetanyl group Chemical group 0.000 claims description 16
- 125000004193 piperazinyl group Chemical group 0.000 claims description 16
- 125000003386 piperidinyl group Chemical group 0.000 claims description 16
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 15
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 15
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 15
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 15
- 230000001404 mediated effect Effects 0.000 claims description 14
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 13
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 13
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 11
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 10
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 9
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 7
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000001425 triazolyl group Chemical group 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010022562 Intermittent claudication Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 2
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 206010008635 Cholestasis Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- 201000001883 cholelithiasis Diseases 0.000 claims description 2
- 231100000359 cholestasis Toxicity 0.000 claims description 2
- 230000007870 cholestasis Effects 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 231100000835 liver failure Toxicity 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000015768 polyposis Diseases 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 abstract description 6
- 230000026731 phosphorylation Effects 0.000 abstract description 4
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 177
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 135
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 90
- 239000000243 solution Substances 0.000 description 63
- 238000006243 chemical reaction Methods 0.000 description 54
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical class [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 34
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 229910052757 nitrogen Inorganic materials 0.000 description 25
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 239000012043 crude product Substances 0.000 description 19
- 239000007787 solid Substances 0.000 description 19
- 239000003208 petroleum Substances 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 108091000080 Phosphotransferase Proteins 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 229940125782 compound 2 Drugs 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 102000020233 phosphotransferase Human genes 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 12
- 229910000024 caesium carbonate Inorganic materials 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000012065 filter cake Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 9
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 9
- 239000012046 mixed solvent Substances 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 8
- 239000005695 Ammonium acetate Substances 0.000 description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 229940043376 ammonium acetate Drugs 0.000 description 8
- 235000019257 ammonium acetate Nutrition 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 8
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 8
- JGZSLGXLSHEGFA-UHFFFAOYSA-N 2-bromo-6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridine Chemical compound BrC1=NC(=CC=C1)C1=NN=CN1C(C)C JGZSLGXLSHEGFA-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- PKIDRZXZOKXVLT-UHFFFAOYSA-N 7-(4-cyclopropylimidazol-1-yl)-2H-isoquinolin-1-one Chemical compound C1(=CC=C2C(=C1)C(=O)NC=C2)N1C=C(C2CC2)N=C1 PKIDRZXZOKXVLT-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 6
- 125000003003 spiro group Chemical group 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 6
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 5
- BWLQKVQZYUNSMW-UHFFFAOYSA-N 2-[3-(6-bromopyridin-2-yl)-1,2,4-triazol-4-yl]propan-1-ol Chemical compound CC(N1C=NN=C1C1=NC(=CC=C1)Br)CO BWLQKVQZYUNSMW-UHFFFAOYSA-N 0.000 description 4
- WCCCDMWRBVVYCQ-UHFFFAOYSA-N 2-bromo-1-cyclopropylethanone Chemical compound BrCC(=O)C1CC1 WCCCDMWRBVVYCQ-UHFFFAOYSA-N 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000002015 acyclic group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 229940030600 antihypertensive agent Drugs 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000002876 beta blocker Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- HQHFAXQNQDZMFK-UHFFFAOYSA-N methyl 2-[2-(dimethylamino)ethenyl]-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC=C1C=CN(C)C HQHFAXQNQDZMFK-UHFFFAOYSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108060008226 thioredoxin Proteins 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 3
- BWLQKVQZYUNSMW-SSDOTTSWSA-N (2R)-2-[3-(6-bromopyridin-2-yl)-1,2,4-triazol-4-yl]propan-1-ol Chemical compound C[C@H](CO)n1cnnc1-c1cccc(Br)n1 BWLQKVQZYUNSMW-SSDOTTSWSA-N 0.000 description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- CBOCDPFTDSZWAL-UHFFFAOYSA-N 4-methoxy-2-methyl-5-nitrobenzoic acid Chemical compound COC1=CC(C)=C(C(O)=O)C=C1[N+]([O-])=O CBOCDPFTDSZWAL-UHFFFAOYSA-N 0.000 description 3
- ODUMWNRMKWTCLW-UHFFFAOYSA-N 7-(4-cyclopropylimidazol-1-yl)-4,4-difluoro-2,3-dihydroisoquinolin-1-one Chemical compound C1=C2C(=CC(=C1)N1C=C(C3CC3)N=C1)C(=O)NCC2(F)F ODUMWNRMKWTCLW-UHFFFAOYSA-N 0.000 description 3
- UCIAVFHSTJCWHL-UHFFFAOYSA-N 7-amino-2-[(2,4-dimethoxyphenyl)methyl]isoquinolin-1-one Chemical compound COC1=CC(OC)=C(CN2C=CC3=C(C=C(N)C=C3)C2=O)C=C1 UCIAVFHSTJCWHL-UHFFFAOYSA-N 0.000 description 3
- QJSWPNBVJSANQK-UHFFFAOYSA-N 7-nitro-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1CNC(=O)C2=CC([N+](=O)[O-])=CC=C21 QJSWPNBVJSANQK-UHFFFAOYSA-N 0.000 description 3
- IPALRSBLKSEKBX-UHFFFAOYSA-N C1(=CC=C2C(=C1)C(=O)NCC2)N1C=C(C2CC2)N=C1 Chemical compound C1(=CC=C2C(=C1)C(=O)NCC2)N1C=C(C2CC2)N=C1 IPALRSBLKSEKBX-UHFFFAOYSA-N 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 3
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000003524 antilipemic agent Substances 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- SGNCOKUHMXLGAH-UHFFFAOYSA-N methyl 6-bromopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(Br)=N1 SGNCOKUHMXLGAH-UHFFFAOYSA-N 0.000 description 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000004323 potassium nitrate Substances 0.000 description 3
- 235000010333 potassium nitrate Nutrition 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JWCHDNRRSHZHHA-UHFFFAOYSA-N 2-[(2,4-dimethoxyphenyl)methyl]-7-nitroisoquinolin-1-one Chemical compound COC1=CC(OC)=CC=C1CN1C(=O)C2=CC([N+]([O-])=O)=CC=C2C=C1 JWCHDNRRSHZHHA-UHFFFAOYSA-N 0.000 description 2
- LXCHAMABVJFENQ-UHFFFAOYSA-N 2-methyl-4,5-dinitrobenzoic acid Chemical compound CC1=CC([N+]([O-])=O)=C([N+]([O-])=O)C=C1C(O)=O LXCHAMABVJFENQ-UHFFFAOYSA-N 0.000 description 2
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- FKOOMSYOAJYBHC-UHFFFAOYSA-N 6-bromo-3-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]quinazolin-4-one Chemical compound CC(C)N1C=NN=C1C2=NC(=CC=C2)N3C=NC4=C(C3=O)C=C(C=C4)Br FKOOMSYOAJYBHC-UHFFFAOYSA-N 0.000 description 2
- QHGDIVMTVIOPDQ-UHFFFAOYSA-N 6-fluoro-7-nitro-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O=C1NCCC2=C1C=C([N+](=O)[O-])C(F)=C2 QHGDIVMTVIOPDQ-UHFFFAOYSA-N 0.000 description 2
- VNUQVKZHEBCTNT-UHFFFAOYSA-N 7-amino-3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1CNC(=O)C2=CC(N)=CC=C21 VNUQVKZHEBCTNT-UHFFFAOYSA-N 0.000 description 2
- DIZIXEGXKKMGHF-UHFFFAOYSA-N 7-amino-6-fluoro-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O=C1NCCC2=C1C=C(N)C(F)=C2 DIZIXEGXKKMGHF-UHFFFAOYSA-N 0.000 description 2
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- UCPTVOZWVQEEBK-UHFFFAOYSA-N C1(CC1)C=1N=CN(C=1)C1=CC=C2CCN(C(C2=C1)=O)C1=NC(=CC=C1)C1=NN=CN1C(C)C Chemical compound C1(CC1)C=1N=CN(C=1)C1=CC=C2CCN(C(C2=C1)=O)C1=NC(=CC=C1)C1=NN=CN1C(C)C UCPTVOZWVQEEBK-UHFFFAOYSA-N 0.000 description 2
- QVLTVILSYOWFRM-UHFFFAOYSA-L CC1=C(C)C(C)([Rh](Cl)Cl)C(C)=C1C Chemical class CC1=C(C)C(C)([Rh](Cl)Cl)C(C)=C1C QVLTVILSYOWFRM-UHFFFAOYSA-L 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000005518 carboxamido group Chemical group 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- TVGKPVDDCDQBRC-UHFFFAOYSA-N methyl 2-methyl-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC=C1C TVGKPVDDCDQBRC-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229960003540 oxyquinoline Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 230000006920 protein precipitation Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- QFCMBRXRVQRSSF-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4-c]pyrrole Chemical compound C1NCC2CNCC21 QFCMBRXRVQRSSF-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- JMWPSCUIQIMVQH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-pyrrolo[3,4-c]pyridine Chemical compound C1NCCC2CNCC21 JMWPSCUIQIMVQH-UHFFFAOYSA-N 0.000 description 1
- 125000004564 2,3-dihydrobenzofuran-2-yl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- AUCVZEYHEFAWHO-UHFFFAOYSA-N 2-(3-fluorophenyl)ethanamine Chemical compound NCCC1=CC=CC(F)=C1 AUCVZEYHEFAWHO-UHFFFAOYSA-N 0.000 description 1
- PPSMYAUEJRADFE-HXUWFJFHSA-N 2-[(5r)-4-[2-[3-(6-methylpyridin-3-yl)oxyphenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound C1=NC(C)=CC=C1OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 PPSMYAUEJRADFE-HXUWFJFHSA-N 0.000 description 1
- BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- MBQKTXUCJWIHQQ-UHFFFAOYSA-N 2-cyclopropyl-1h-imidazole Chemical compound C1CC1C1=NC=CN1 MBQKTXUCJWIHQQ-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- XXXOBNJIIZQSPT-UHFFFAOYSA-N 2-methyl-4-nitrobenzoic acid Chemical compound CC1=CC([N+]([O-])=O)=CC=C1C(O)=O XXXOBNJIIZQSPT-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YWPMKTWUFVOFPL-UHFFFAOYSA-N 3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NCCC2=C1 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 description 1
- XKEYAOJRNJYJMM-UHFFFAOYSA-N 3,6-diazabicyclo[3.2.0]heptane Chemical compound C1NCC2CNC21 XKEYAOJRNJYJMM-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- UUFGYUFAPLFHQI-UHFFFAOYSA-N 6-(4-cyclopropylimidazol-1-yl)-3-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]quinazolin-4-one Chemical compound CC(C)N1C=NN=C1C1=CC=CC(=N1)N1C=NC2=CC=C(C=C2C1=O)N1C=NC(=C1)C1CC1 UUFGYUFAPLFHQI-UHFFFAOYSA-N 0.000 description 1
- MPBBJHFKDHDIRZ-UHFFFAOYSA-N 6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-amine Chemical compound CC(C)N1C=NN=C1C1=CC=CC(N)=N1 MPBBJHFKDHDIRZ-UHFFFAOYSA-N 0.000 description 1
- FVPXVDTWEBFLLE-UHFFFAOYSA-N 6-bromo-4-fluoro-2,3-dihydroinden-1-one Chemical compound FC1=CC(Br)=CC2=C1CCC2=O FVPXVDTWEBFLLE-UHFFFAOYSA-N 0.000 description 1
- CUDQTPCGOPBJEO-UHFFFAOYSA-N 6-bromopyridine-2-carbohydrazide Chemical compound NNC(=O)C1=CC=CC(Br)=N1 CUDQTPCGOPBJEO-UHFFFAOYSA-N 0.000 description 1
- USEKKPNQWXOTLF-UHFFFAOYSA-N 6-chloro-4-(4-chlorophenoxy)-1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=CC(Cl)=CC=C1OC1=NC(Cl)=NC2=C1C=NN2 USEKKPNQWXOTLF-UHFFFAOYSA-N 0.000 description 1
- QAYARJVVFMRVQJ-UHFFFAOYSA-N 6-fluoro-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O=C1NCCC2=CC(F)=CC=C21 QAYARJVVFMRVQJ-UHFFFAOYSA-N 0.000 description 1
- UQINUDUJIANJLV-UHFFFAOYSA-N 7-(4-cyclopropylimidazol-1-yl)-2-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]isoquinolin-1-one Chemical compound C(C)(N1C=NN=C1C1=NC(N2C(=O)C3=CC(=CC=C3C=C2)N2C=C(C3CC3)N=C2)=CC=C1)C UQINUDUJIANJLV-UHFFFAOYSA-N 0.000 description 1
- MXVBSYHDRZSMFO-UHFFFAOYSA-N 7-(4-cyclopropylimidazol-1-yl)-4-fluoro-2-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]isoquinolin-1-one Chemical compound C1=C2C(=CC(N3C=C(C4CC4)N=C3)=C1)C(=O)N(C=C2F)C1=NC(=CC=C1)C=1N(C=NN=1)C(C)C MXVBSYHDRZSMFO-UHFFFAOYSA-N 0.000 description 1
- SWDNXUOHYHBRNG-UHFFFAOYSA-N 7-bromo-5-fluoro-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O=C1NCCC2=C1C=C(Br)C=C2F SWDNXUOHYHBRNG-UHFFFAOYSA-N 0.000 description 1
- YJZDQXBQGAXXGP-UHFFFAOYSA-N 7-nitro-2h-isoquinolin-1-one Chemical compound C1=CNC(=O)C2=CC([N+](=O)[O-])=CC=C21 YJZDQXBQGAXXGP-UHFFFAOYSA-N 0.000 description 1
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 108010075639 MAP Kinase Kinase Kinase 5 Proteins 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- UXRZLDREKITWRO-UHFFFAOYSA-N P(c1ccccc1)c1ccccc1.CC1(C)c2ccccc2Oc2ccccc12 Chemical compound P(c1ccccc1)c1ccccc1.CC1(C)c2ccccc2Oc2ccccc12 UXRZLDREKITWRO-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229940010048 aluminum sulfate Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical compound C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WNTGVOIBBXFMLR-UHFFFAOYSA-N bicyclo[3.3.1]nonane Chemical class C1CCC2CCCC1C2 WNTGVOIBBXFMLR-UHFFFAOYSA-N 0.000 description 1
- KVLCIHRZDOKRLK-UHFFFAOYSA-N bicyclo[4.2.1]nonane Chemical compound C1C2CCC1CCCC2 KVLCIHRZDOKRLK-UHFFFAOYSA-N 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004246 indolin-2-yl group Chemical group [H]N1C(*)=C([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- LNDFAPOPMDWHOO-UHFFFAOYSA-N methyl 4-methoxy-2-methyl-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=C(OC)C=C1C LNDFAPOPMDWHOO-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene group Chemical group C1=CC=C2C=CC=C12 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to simultaneously ring class ASK1 inhibitor and its applications, and in particular to logical formula (I) compound represented, its pharmaceutically acceptable salt, ester or its stereoisomer.The invention further relates to the preparation method of the compound, the pharmaceutical preparation comprising the compound and pharmaceutical compositions.The compound of the present invention can effectively inhibit the amino acid phosphorylation of ASK1, inhibit the activation of ASK1;Therefore it can treat and/or prevent the disease and related disease of ASK1 mediation.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a compound shown as a formula (I), a pharmaceutically acceptable salt, an ester or a stereoisomer thereof, a pharmaceutical composition and a preparation containing the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer thereof, a method for preparing the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer thereof, and application of the compound, the pharmaceutically acceptable salt, the ester or the stereoisomer thereof in preparation of medicines for treating and/or preventing ASK 1-mediated diseases and related diseases.
Background
Mitogen-activated protein kinases (MAPKs) exist as sequentially activated MAPKKKs, MAPKKs, MAPKs. Environmental signals affect MAPKKK, which in turn phosphorylates MAPKK, phosphorylates specific MAPK, which then mediates cellular responses, including cell growth, differentiation, apoptosis and inflammation, by phosphorylating cellular substrates.
Apoptosis signal-regulating kinase 1(ASK1) is a member of the MAPKKK family, and is an oligomer-like compound linked to the C-helical region, the N-helical region is linked to thioredoxin (Trx), and Trx inhibits activation of ASK 1. Under the stimulation conditions of oxidative stress, endoplasmic reticulum pressure, intramolecular calcium concentration, GPCR signal and the like, thioredoxin of ASK1 is dissociated, and the self amino acid (human: Thr838, mouse: Thr845) of ASK1 is subjected to autophosphorylation, so that MAPKK (such as MAPKK3/MAPKK6, MAPKK4/MAPKK7) is phosphorylated; p38 and JNK downstream were subsequently phosphorylated and activated. Activation of this pathway is closely related to tumor growth, metabolic diseases and neurological diseases.
The ASK1 inhibitor has the action mechanism of inhibiting the phosphorylation of ASK1 and blocking the activation of downstream channels, thereby achieving the treatment effect on tumor diseases, metabolic diseases and neurodegenerative diseases.
At present, only GS-4997 of Gilead is in clinical stage as ASK1 inhibitor researched internationally, PhaseIII (stage III) is being developed, PhaseII (stage II) research on diabetic nephropathy, pulmonary hypertension and nonalcoholic steatohepatitis is completed, and the effectiveness and safety of the target are proved through the verification of PhaseII.
Disclosure of Invention
The invention aims to provide a fused ring ASK1 inhibitor and application thereof. The specific technical scheme is as follows:
the invention firstly provides a compound shown in a general formula (I), and pharmaceutically acceptable salt, ester or stereoisomer thereof:
wherein,
X、X1、X2、X3、X4、X5each independently selected from C, CR8Or N;
R1selected from optionally substituted by one or more Q1Substituted C1-10Alkyl radical, C2-10Alkenyl radical, C1-10Alkoxy, 3-to 8-membered cycloalkyl, C2-10Alkynyl, aryl, heteroaryl or heterocyclyl;
each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl, halo C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino, 3-to 8-membered cycloalkyl, 3-to 8-membered heterocyclyl, phenyl, phenoxy, -O-R8、-C(O)-R8、-OC(O)-R8、-C(O)-O-R8、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-R9、-N(R8)-C(O)-N(R8)(R9) or-C (O) -N (R)8)(R9) In which C is1-6Alkyl, 3-8 membered cycloalkyl, 3-8 membered heterocyclyl, phenyl, phenoxy optionally substituted with one or more C1-6Alkyl, 3-8 membered cycloalkyl, C1-6Alkoxy, hydroxy, amino, carboxy or halogen substitution;
or R1And X1Together with the N to which they are attached form a heterocyclic, aryl or heteroaryl groupSaid heterocyclyl, aryl or heteroaryl being optionally substituted with one or more alkyl, hydroxy or halogen;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, hydroxy C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino, C1-6Alkylthio radical, C1-6Alkylcarbonyl group, C1-6Alkoxy radical C1-6Alkyl radical, C1-6Alkylcarbonyloxy, C1-6Alkylsulfonyl radical, C1-6Alkylaminosulfonyl, di (C)1-6Alkyl) aminosulfonyl, C1-6Alkylsulfonylamino or C1-6An alkylsulfonyloxy group;
R3selected from absent, hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;
each Q2Independently selected from C1-6Alkyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen, cyano, nitro, haloC1-6Alkoxy radical, C1-6Alkylamino, oxo, -O-R8、-O-C(O)-R8、-O-C(O)-N(R8)(R9)、-S-R8、-N(R8)(R9)、-S(=O)-R8、-S(=O)2R8、-O-S(=O)2R8、-S(=O)2-N(R8)(R9)、-S(=O)2-OR8、-N(R8)-C(O)-R9、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-N(R8)(R9)、-C(O)-R8、-C(O)-O-R8、-C(O)-N(R8)-R9or-N (R)8)-S(=O)2-R9Wherein said C is1-6The alkyl, 3-8 membered cycloalkyl, aryl, heteroaryl or heterocyclyl is further optionally substituted with one or more halogen, hydroxy, amino, cyano, nitro, carboxy, oxo, C1-6Alkyl or-O-R8Substitution;
each R8And R9Each independently selected from hydrogen and C1-6Alkyl, 3-8 membered cycloalkyl, or when R is8And R9When attached to the same N atom, R8And R9Together with the N atom to which they are attached form a 3-12 membered heterocyclic ring;
selected from single bonds or double bonds.
Some embodiments of the present invention relate to compounds of the foregoing general formula (I), a pharmaceutically acceptable salt, ester, or stereoisomer thereof, wherein,
X、X1、X2、X3、X4、X5each independently selected from C, CR8Or N;
R1selected from optionally substituted by one or more Q1Substituted C1-6Alkyl radical, C2-6Alkenyl radical, C1-6Alkoxy, 3-to 8-membered cycloalkyl, C2-6Alkynyl, 6-14 membered aryl, 5-14 membered heteroaryl or 3-12 membered heterocyclyl;
each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl, halo C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino, 3-to 8-membered cycloalkyl, heterocyclyl, phenyl, phenoxy, -O-R8、-C(O)-R8、-OC(O)-R8、-C(O)-O-R8、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-R9、-N(R8)-C(O)-N(R8)(R9) or-C (O) -N (R)8)(R9) In which C is1-6Alkyl, 3-8 membered cycloalkyl, heterocyclyl, phenyl, phenoxy optionally substituted by one or more C1-6Alkyl, 3-8 membered cycloalkyl, C1-6Alkoxy, hydroxy, amino, carboxy or halogen substitution;
or R1And X1Bonded to form a 5-12 membered heterocyclyl, 6-12 membered aryl or 5-12 membered heteroaryl, said 5-12 membered heterocyclyl, 6-12 membered aryl or 5-12 membered heteroaryl being optionally substituted with one or more C1-6Alkyl, hydroxy or halogen substitution;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, hydroxy C1-6Alkoxy radical, C1-6An alkylamino group;
R3selected from absent, hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, 6-14 membered aryl, 5-14 membered heteroaryl, 3-12 membered cycloalkyl or 3-12 membered heterocyclyl;
each Q2Independently selected from C1-6Alkyl, 3-8 membered cycloalkyl C1-6Alkyl, 6-14 membered aryl C1-6Alkyl, 5-14 membered heteroaryl C1-6Alkyl, 3-12 membered heterocyclic group C1-6Alkyl, halogen, cyano, nitro, oxo, -O-R8、-O-C(O)-R8、-O-C(O)-N(R8)(R9)、-S-R8、-N(R8)(R9)、-S(=O)-R8、-S(=O)2R8、-O-S(=O)2R8、-S(=O)2-N(R8)(R9)、-S(=O)2-OR8、-N(R8)-C(O)-R9、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-N(R8)(R9)、-C(O)-R8、-C(O)-O-R8、-C(O)-N(R8)-R9Or N (R)8)-S(=O)2-R9Wherein said C is1-6Alkyl, 3-8 membered cycloalkyl, 6-14 membered aryl, 5-14 membered heteroaryl or 3-12 membered heterocyclyl is further optionally substituted with one or more halogen, hydroxy, amino, cyano, nitro, carboxy, oxo, C1-6Alkyl or-O-R8Substitution;
R8and R9Each independently selected from hydrogen and C1-6Alkyl, 3-8 membered cycloalkyl, or when R is8And R9When attached to the same N atom, R8And R9Together with the N atom to which they are attached form a 3-12 membered heterocyclic ring;
selected from single bonds or double bonds.
Some embodiments of the present invention relate to a compound described by the foregoing general formula (I), a pharmaceutically acceptable salt, ester, or stereoisomer thereof: wherein,
X2、X3、X4、X5at least one is selected from N;
R1selected from optionally substituted by one or more Q1Substituted C1-6Alkyl radical, C2-6Alkenyl radical, C1-6Alkoxy, 3-to 8-membered cycloalkyl, C2-6Alkynyl, 6-12 membered aryl, 5-12 membered heteroaryl or 3-10 membered heterocyclyl;
each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl, halo C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino, 3-to 8-membered cycloalkyl, 3-to 8-membered heterocyclyl, phenyl,Phenoxy, -O-R8、-C(O)-R8、-OC(O)-R8、-C(O)-O-R8、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-R9、-N(R8)-C(O)-N(R8)(R9) or-C (O) -N (R)8)(R9);
Or R1And X1Together with the N to which they are attached form a 5-10 membered heterocyclyl, 6-12 membered aryl or 5-10 membered heteroaryl, said 5-10 membered heterocyclyl, 6-12 membered aryl or 5-10 membered heteroaryl being optionally substituted by one or more C1-6Alkyl, hydroxy or halogen substitution;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, hydroxy C1-6Alkoxy radical, C1-6An alkylamino group;
R3selected from absent, hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, 6-to 10-membered aryl, 5-to 12-membered heteroaryl, 3-to 10-membered cycloalkyl or 3-to 10-membered heterocyclyl;
each Q2Independently selected from C1-6Alkyl, 3-8 membered cycloalkyl C1-6Alkyl, 6-14 membered aryl C1-6Alkyl, 5-14 membered heteroaryl C1-6Alkyl, 3-12 membered heterocyclic group C1-6Alkyl, halogen, cyano, nitro, halogeno C1-6Alkoxy, oxo, -O-R8、-O-C(O)-R8、-O-C(O)-N(R8)(R9)、-S-R8、-N(R8)(R9)、-S(=O)-R8、-S(=O)2R8、-O-S(=O)2R8、-S(=O)2-N(R8)(R9)、-S(=O)2-OR8、-N(R8)-C(O)-R9、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-N(R8)(R9)、-C(O)-R8、-C(O)-O-R8、-C(O)-N(R8)-R9or-N (R)8)-S(=O)2-R9Wherein said C is1-6Alkyl, 3-8 membered cycloalkyl, 6-14 membered aryl, 5-14 membered heteroaryl or 3-12 membered heterocyclyl is further optionally substituted with one or more halogen, hydroxy, amino, cyano, nitro, carboxy, oxo, C1-6Alkyl or-O-R8Substitution;
each R8And R9Each independently selected from hydrogen and C1-6Alkyl, 3-8 membered cycloalkyl, or when R is8And R9When attached to the same N atom, R8And R9Together with the N atom to which they are attached form a 3-12 membered heterocyclic ring;
selected from single bonds or double bonds.
In some embodiments of the invention, the aforementioned compound, a pharmaceutically acceptable salt thereof, an ester thereof, or a stereoisomer thereof, has a structure represented by formula (II),
wherein,
X、X1each independently selected from C, CR8Or N;
R1selected from optionally substituted by one or more Q1Substituted C1-6Alkyl radical, C2-6Alkenyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl or 3-8 membered heterocyclyl;
each Q1Independently selected from halogen, cyano, hydroxy, amino,Nitro, carboxyl, C1-6Alkyl, halo C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino, 3-to 8-membered cycloalkyl, 3-to 8-membered heterocyclyl, phenyl, phenoxy, -O-R8、-C(O)-R8、-OC(O)-R8、-C(O)-O-R8、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-R9、-N(R8)-C(O)-N(R8)(R9) or-C (O) -N (R)8)(R9);
Or R1And X1Together with the N to which they are attached, form a 5-8 membered heterocyclyl, 6-10 membered aryl or 5-8 membered heteroaryl, said 5-8 membered heterocyclyl, 6-10 membered aryl or 5-8 membered heteroaryl being optionally substituted with one or more C1-6Alkyl, hydroxy or halogen substitution;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, hydroxy C1-6Alkoxy or C1-6An alkylamino group;
R3selected from absent, hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, 6-to 8-membered aryl, 5-to 10-membered heteroaryl, 3-to 8-membered cycloalkyl or 3-to 8-membered heterocyclyl;
each Q2Independently selected from C1-6Alkyl, 3-8 membered cycloalkyl C1-6Alkyl, 3-8 membered heterocyclic group C1-6Alkyl, halo C1-6Alkoxy, halogen, cyano, nitro, -O-R8、-O-C(O)-R8、-O-C(O)-N(R8)(R9)、-S-R8、-N(R8)(R9)、-S(=O)-R8、-S(=O)2R8、-O-S(=O)2R8、-S(=O)2-N(R8)(R9)、-S(=O)2-OR8、-N(R8)-C(O)-R9、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-N(R8)(R9)、-C(O)-R8、-C(O)-O-R8、-C(O)-N(R8)-R9or-N (R)8)-S(=O)2-R9Wherein said C is1-6Alkyl, 3-8 membered cycloalkyl, 3-8 membered heterocyclyl is further optionally substituted with one or more halogen, hydroxy, amino, cyano, nitro, carboxy, oxo, C1-6Alkyl or-O-R8Substitution;
each R8And R9Each independently selected from hydrogen or C1-6An alkyl group;
selected from single bonds or double bonds.
Some embodiments of the invention relate to the aforementioned compound, a pharmaceutically acceptable salt, ester, or stereoisomer thereof, having a structure represented by formula (III),
wherein,
R1selected from the group consisting of optionally substituted 1-3Q1Substituted C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl or 3-8 membered heterocyclyl, each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl radical, C1-6Alkoxy radical, C1-6Alkylcarbonyl group, C1-6Alkoxycarbonyl group, C1-6Alkylamido, aminoacyl, C1-6Alkylaminoacyl, di (C)1-6Alkyl) aminoacyl, halo C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino or 3-8 membered ringAn alkyl group;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, hydroxy C1-6Alkoxy or C1-6An alkylamino group;
R3selected from hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from the group consisting of optionally substituted 1-3Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, phenyl, 5-8 membered heteroaryl, or 3-6 membered heterocyclyl;
each Q2Independently selected from C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl C1-6Alkyl, 3-6 membered heterocyclic group C1-6Alkyl, halogen, cyano, hydroxy, amino, nitro, haloC1-6Alkoxy radical, C1-6Alkylamino radical, C1-6Alkylcarbonyl group, C1-6Alkylcarbonyloxy, C1-6Alkyl mercapto group, C1-6Alkylsulfonyl radical, C1-6Alkyloxycarbonyl, C1-6Alkylamido radical, C1-6Alkylaminoacyl, C1-6Alkylsulfonylamino, wherein said C1-6The alkyl, 3-6 membered cycloalkyl or 3-6 membered heterocyclyl is further optionally substituted with 1 to 3 halogen, hydroxy, amino, cyano, nitro, carboxy, C1-6Alkyl substitution;
selected from single bonds or double bonds.
Some embodiments of the present invention relate to a compound described by the foregoing general formula (III), a pharmaceutically acceptable salt, ester, or stereoisomer thereof,
wherein,
R1selected from the group consisting of optionally substituted 1-3Q1Substituted C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl, each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl radical, C1-6Alkoxy radical, C1-6Alkoxycarbonyl, aminoacyl, C1-6Alkylaminoacyl, di (C)1-6Alkyl) aminoacyl, C1-6Alkylamino or di (C)1-6Alkyl) amino;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl or halo C1-6An alkoxy group;
R3selected from hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from the group consisting of optionally substituted 1-3Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, phenyl or 5-8 membered heteroaryl;
each Q2Independently selected from C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl C1-6Alkyl, 3-6 membered heterocyclyl, -6 membered heterocyclyl C1-6Alkyl, halogen, hydroxy or amino, wherein said C1-6The alkyl, 3-6 membered cycloalkyl or 3-6 membered heterocyclyl is further optionally substituted with 1 to 3 halogen, hydroxy, amino, cyano, nitro, carboxy, C1-6Alkyl substitution;
selected from single bonds or double bonds.
Some embodiments of the present invention relate to a compound described by the foregoing general formula (III), a pharmaceutically acceptable salt, ester, or stereoisomer thereof,
R1selected from optionally 1-2Q1Substituted C1-4Alkyl radical, C1-4Alkoxy, 3-6 membered cycloalkyl, each Q1Independently selected from halogen, hydroxy, amino, C1-4Alkyl radical, C1-4Alkoxy radical, C1-4Alkoxycarbonyl, aminoacyl, C1-4Alkylaminoacyl, di (C)1-4Alkyl) aminoacyl, C1-4Alkylamino or di (C)1-4Alkyl) amino;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxy, amino, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halo C1-4An alkoxy group;
R3selected from hydrogen, halogen, C1-4Alkyl, halo C1-4Alkyl, hydroxy C1-4Alkyl or C1-4An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally 1-2Q2Substituted C1-4Alkyl radical, C1-4Alkylamino radical, C1-4Alkoxy, phenyl or 5-6 membered heteroaryl;
each Q2Independently selected from C1-4Alkyl radical, C1-4Alkoxy, 3-6 membered cycloalkyl C1-4Alkyl, 3-6 membered heterocyclic group C1-4Alkyl, halogen, hydroxy or amino, wherein said C1-4The alkyl group, 3-6 membered cycloalkyl group or 3-6 membered heterocyclic group is further optionally substituted by 1 to 3, preferably 1 to 2, halogens, hydroxyl group, amino group, C1-4Alkyl substitution;
selected from single bonds or double bonds.
Some embodiments of the present invention relate to a compound described by the foregoing general formula (III), a pharmaceutically acceptable salt, ester, or stereoisomer thereof,
wherein,
R1selected from optionally 1-2Q1Substituted methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, or morpholinyl, each Q1Independently selected from the group consisting of halogen, cyano, hydroxy, amino, nitro, carboxy, methyl, ethyl, methoxy, ethoxy, propoxy, isopropoxy, methoxycarbonyl, ethoxycarbonyl, methylamino, ethylamino, dimethylamino, diethylamino, aminoacyl, methylaminoacyl, ethylamyl, dimethylaminyl, diethylamino;
R2、R4、R6、R7each independently selected from hydrogen, fluoro, bromo, chloro, iodo, hydroxy, amino, cyano, nitro, carboxy, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, trifluoromethyl, trifluoroethyl, difluoromethoxy or trifluoromethoxy;
R3selected from hydrogen, fluoro, bromo, chloro, iodo, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl or formyl;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally 1-2Q2Substituted phenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridyl or pyrimidinyl;
each Q2Independently selected from methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, methoxy, cyclopropyl, cyclopropylmethylGroup, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, wherein said methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl are further optionally substituted by 1 to 3, preferably 1 to 2, halogens, hydroxy, amino, cyano, nitro, carboxy, methyl, ethyl, propyl, isopropyl;
selected from single bonds or double bonds.
In some embodiments of the invention, the aforementioned compound, a pharmaceutically acceptable salt thereof, an ester thereof, or a stereoisomer thereof, has a structure represented by formula (IV),
wherein,
R1selected from the group consisting of optionally substituted 1-3Q1Substituted C1-6Alkyl radical, C1-6Alkoxy or 3-6 membered cycloalkyl, each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl radical, C1-6Alkoxy, aminoacyl, C1-6Alkylaminoacyl, di (C)1-6Alkyl) aminoacyl, C1-6Alkylamino or di (C)1-6Alkyl) amino;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl or halogenGeneration C1-6An alkoxy group;
R5selected from the group consisting of optionally substituted 1-3Q2Substituted phenyl or 5-8 membered heteroaryl;
each Q2Independently selected from C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl C1-6Alkyl, 3-6 membered heterocyclyl or 3-6 membered heterocyclyl C1-6Alkyl, wherein the 3-6 membered cycloalkyl or 3-6 membered heterocyclyl is further optionally substituted with 1 to 3 halogens, hydroxy, amino, cyano, nitro, carboxy, C1-6Alkyl substitution.
In some embodiments, the present invention relates to a compound having a structure represented by the general formula (IV), a pharmaceutically acceptable salt thereof, an ester thereof, or a stereoisomer thereof,
R1selected from the group consisting of optionally substituted 1-3Q1Substituted C1-4Alkyl radical, C1-4Alkoxy or 3-6 membered cycloalkyl, each Q1Independently selected from halogen, hydroxy, amino, C1-4Alkyl radical, C1-4Alkoxy, aminoacyl, C1-4Alkylaminoacyl, di (C)1-4Alkyl) aminoacyl, C1-4Alkylamino or di (C)1-4Alkyl) amino;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxy, amino, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halo C1-4An alkoxy group;
R5selected from the group consisting of optionally substituted 1-3Q2Substituted phenyl or 5-6 membered heteroaryl;
each Q2Independently selected from C1-4Alkyl radical, C1-4Alkoxy, 3-6 membered cycloalkyl C1-4Alkyl, 3-6 membered heterocyclyl or 3-6 membered heterocyclyl C1-4Alkyl, wherein the 3-6 membered cycloalkyl or 3-6 membered heterocyclyl is further optionally substituted with 1-3 halogens, hydroxy, amino, C1-4Alkyl substitution.
Some embodiments of the present invention relate to a compound described by the foregoing general formula (IV), a pharmaceutically acceptable salt, ester, or stereoisomer thereof,
wherein,
R1selected from optionally 1-2Q1Substituted methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, said substituents Q1Selected from the group consisting of halogen, cyano, hydroxy, amino, nitro, carboxy, methyl, ethyl, methoxy, ethoxy, propoxy, isopropoxy, methylamino, ethylamino, dimethylamino, diethylamino, aminoacyl, methylaminoacyl, ethylaminol, dimethylaminyl, diethylaminoacyl; (ii) a
R2、R4、R6、R7Each independently selected from hydrogen, fluoro, bromo, chloro, iodo, hydroxy, amino, cyano, nitro, carboxy, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, trifluoromethyl, trifluoroethyl, or trifluoromethoxy;
R5selected from optionally 1-2Q2Substituted phenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolylpyridinyl or pyrimidinyl;
each Q2Independently selected from methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, methoxy, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, wherein said cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl is further optionally substituted with 1 to 2 halogens, hydroxy, amino, cyano, methoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, thiazolidinyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, further optionally substituted with 1 to 2 halogens, hydroxy, amino, cyano, or a pharmaceutically acceptable saltNitro, carboxyl, methyl, ethyl, propyl or isopropyl.
In some embodiments of the invention, the aforementioned compound, a pharmaceutically acceptable salt thereof, an ester thereof, or a stereoisomer thereof, has a structure represented by formula (V),
wherein,
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl or halo C1-6An alkoxy group;
R3selected from hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted phenyl or 5-8 membered heteroaryl;
each Q2Independently selected from C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl C1-6Alkyl, 3-6 membered heterocyclyl or 3-6 membered heterocyclyl C1-6Alkyl, wherein the 3-6 membered cycloalkyl or 3-6 membered heterocyclyl is further optionally substituted with one or more halo, hydroxy, amino, cyano, nitro, carboxy.
Some embodiments of the present invention relate to a compound of the foregoing general formula (V), a pharmaceutically acceptable salt, ester, or stereoisomer thereof,
wherein,
R2、R4、R6、R7each independently selected from hydrogen, fluorine, bromine, chlorine, iodine, hydroxyl, amino, cyano, nitro, carboxyl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy and ethylOxy, propoxy, isopropoxy, tert-butoxy, trifluoromethyl, trifluoroethyl or trifluoromethoxy;
R3selected from hydrogen, fluoro, bromo, chloro, iodo, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl or formyl;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted phenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridyl or pyrimidinyl;
each Q2Selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, methoxy, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, wherein the cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl are further optionally substituted with one or more halogen, hydroxy, amino, cyano, nitro, carboxy, methyl, ethyl, propyl or isopropyl groups.
The selection of any substituent in any embodiment described in the present invention can be combined with each other, and the combined technical scheme is still included in the protection scope of the present invention.
In some embodiments of the present invention, the structure of a compound of formula (I), (II), (III), (IV) or (V), a pharmaceutically acceptable salt, ester or stereoisomer thereof, is shown in table 1:
TABLE 1
The term "pharmaceutically acceptable salts" as used herein refers to pharmaceutically acceptable acid and base addition salts, which may be prepared from inorganic and organic acids; addition salts of pharmaceutically acceptable bases can be prepared from organic or inorganic bases.
The "ester" as referred to herein means a pharmaceutically acceptable ester, particularly an ester which is hydrolyzed in vivo and includes an ester which is easily decomposed in the human body to leave the parent compound (the compound represented by the general formula (I), (II), (III), (IV) or (V)) or a salt thereof. In some embodiments of the invention, wherein the pharmaceutically acceptable ester comprises: derived from pharmaceutically acceptable aliphatic carboxylic acids and phosphoric acid (salts).
"stereoisomer" of a compound represented by the general formula (I), (II), (III), (IV) or (V) of the present invention means that an enantiomer is produced when asymmetric carbon atoms are present in the compound represented by the general formula (I), (II), (III), (IV) or (V); when the compound has a carbon-carbon double bond or a cyclic structure, cis-trans isomers can be generated; tautomers can arise when a compound is present as a ketone or oxime, and in some embodiments of the invention, stereoisomers include, but are not limited to: enantiomers, diastereomers, racemates, cis-trans isomers, tautomers, geometrical isomers, epimers and mixtures thereof.
The present invention also provides a process for the preparation of a compound of the general formula (I) as defined above, wherein the process comprises:
(1) the preparation method comprises the following steps of reacting a compound shown as a general formula (I-1) with a compound shown as a general formula (I-2) to obtain a compound shown as a general formula (I);
(2) the second preparation method comprises the step of reacting the compound shown in the general formula (I-3) with the compound shown in the general formula (I-2) to obtain a compound shown in the general formula (I-4); the nitro group in the compound shown in the general formula (I-4) is subjected to functional group conversion reaction to obtain a compound shown in the general formula (I);
further, the present invention provides a method for preparing the compound represented by the aforementioned general formula (III), wherein the method comprises:
(1) the preparation method comprises the following steps of reacting a compound shown as a general formula (III-1) with a compound shown as a general formula (III-2) to obtain a compound shown as a general formula (III);
(2) the second preparation method comprises the step of reacting the compound shown in the general formula (III-3) with the compound shown in the general formula (III-2) to obtain a compound shown in the general formula (III-4); the nitro group in the compound shown in the general formula (III-4) is subjected to functional group conversion reaction to obtain a compound shown in the general formula (III);
wherein substituent a is selected from a leaving group, such as halogen.
The "functional group transformation reaction" can be achieved by known chemical synthesis methods, including but not limited to substitution reaction, addition reaction, elimination reaction, dehydration reaction, hydrolysis reaction, oxidation reaction, esterification reaction, etc., which are well known to those skilled in the chemical field, and the present invention is not limited thereto; in the specific implementation process, the reaction can be realized through one-step reaction or multi-step reaction.
In addition, some necessary starting materials, for example, materials for synthesizing intermediates, can be synthesized according to similar procedures and methods described in the handbook of organic chemistry, and the present invention is not limited thereto.
R in the above reaction equation1、R2、R3、R4、R5、R6、R7、n、X、X1、X2、X3、X4、X5As defined hereinbefore, for example, in any one of the general formulae (I) to (V).
The invention also provides intermediates useful in the synthesis of compounds of formula (III) having the following structural formula:
wherein substituent a is selected from a leaving group, such as halogen; r1、R2、R3、R4、R5、R6、R7N is as defined above.
The invention also provides a pharmaceutical composition which contains the compound shown in the general formula (I), (II), (III), (IV) or (V), pharmaceutically acceptable salt, ester or stereoisomer thereof, and optionally one or more second therapeutic active agents. The second therapeutically active agent may be used in combination with ASK1 for the alleviation or treatment of related disorders mediated thereby, such as cardiovascular disorders, pulmonary disorders, metabolic disorders, peripheral vascular disorders, gastrointestinal disorders;
the cardiovascular diseases include, but are not limited to, angina pectoris, arrhythmia, intermittent claudication, myocardial infarction, heart failure, or recurrent ischemia. Therapeutically active agents suitable for the combination treatment of cardiovascular-related diseases include, but are not limited to, anti-angina agents, anti-heart failure agents, anti-thrombotic agents, anti-arrhythmic agents, anti-hypertensive agents, and lipid-lowering agents. Anti-angina agents include, but are not limited to, beta-blockers, calcium channel blockers, and nitrates and the like; agents used to treat heart failure include diuretics, ACE inhibitors, vasodilators, cardiac glycosides, and the like; antithrombotic agents including but not limited to platelet inhibitors, anticoagulants, and thrombolytic agents, and the like; antiarrhythmic agents include, but are not limited to, sodium channel blockers, beta-blockers, calcium channel blockers, agents that extend the action potential time course, and adenosine, among others. Antihypertensive agents include, but are not limited to, alpha-1-adrenergic antagonists, beta-adrenergic antagonists, central alpha-adrenergic receptor agonists, combined alpha/beta-adrenergic antagonists, adrenergic neuron blockers, central nervous system acting antihypertensive agents, anti-angiotensin II agents, ACE inhibitors, angiotensin-II receptor antagonists, calcium channel blockers, vasodilators, potassium channel activators and the like; lipid lowering agents include, but are not limited to, statins, fibrates, nicotinic acids, bile acid sequestrants, cholesterol absorption inhibition, and the like.
The lung disease refers to any disease related to the lung, including but not limited to asthma, chronic obstructive pulmonary disease, bronchitis and emphysema. Therapeutically active agents suitable for the combination treatment of pulmonary diseases include, but are not limited to, bronchodilators, including β 2 agonists, anticholinergics, corticosteroids, and electrolyte supplements.
The metabolic diseases include but are not limited to diabetes, metabolic syndrome, dyslipidemia, obesity, glucose intolerance, hypertension, high serum cholesterol, higher triglycerides and the like. Active agents suitable for the combined treatment of metabolic disorders include, but are not limited to, antihypertensive agents and lipid-lowering agents.
Such peripheral vascular disease includes, but is not limited to, peripheral arterial disease.
The gastrointestinal diseases include but are not limited to gastroesophageal reflux disease, inflammatory bowel disease, gastroenteritis, gastritis, peptic ulcer disease, pancreatitis and the like. Suitable agents for the combined treatment of gastrointestinal disorders include, but are not limited to, proton pump inhibitors, H2 blockers, prostaglandins, aluminum sulfate, and antacids, among others.
Patients with acute cardiovascular disease are treated with ASK1 inhibitors, and the associated condition may be treated with antibiotics, analgesics, and/or anxiolytics.
In some embodiments of the invention, the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers and/or diluents.
The invention also provides a pharmaceutical preparation which contains the compound shown in the general formula (I), (II), (III), (IV) or (V), the pharmaceutically acceptable salt, ester or stereoisomer thereof, and one or more pharmaceutical carriers and/or diluents; the pharmaceutical preparation is any clinically or pharmaceutically acceptable dosage form.
In some embodiments of the invention, the pharmaceutical formulations described above may be administered to a patient or subject in need of such treatment by oral, parenteral, rectal, or pulmonary administration, and the like. For oral administration, the pharmaceutical composition can be prepared into oral preparations, for example, conventional oral solid preparations such as tablets, capsules, pills, granules and the like; it can also be made into oral liquid, such as oral solution, oral suspension, syrup, etc. When the composition is formulated into oral preparations, appropriate filler, binder, disintegrating agent, lubricant, etc. can be added. For parenteral administration, the pharmaceutical preparations can also be prepared into injections, including injections, sterile powders for injection, and concentrated solutions for injection. The injection can be prepared by conventional method in the existing pharmaceutical field, and can be prepared without adding additives or adding suitable additives according to the properties of the medicine. For rectal administration, the pharmaceutical composition may be formulated as a suppository or the like. For pulmonary administration, the pharmaceutical composition may be formulated as an inhalant or a spray.
The pharmaceutically acceptable carrier and/or diluent useful in the pharmaceutical composition or pharmaceutical formulation of the present invention may be any conventional carrier and/or diluent in the art of pharmaceutical formulation, and the selection of a particular carrier and/or diluent will depend on the mode of administration or the type and state of the disease used to treat a particular patient. The preparation of suitable pharmaceutical compositions for a particular mode of administration is well within the knowledge of those skilled in the pharmaceutical art. For example, the pharmaceutically acceptable carrier and/or diluent may include solvents, diluents, dispersing agents, suspending agents, surfactants, isotonic agents, thickening agents, emulsifiers, binders, lubricants, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, ion exchangers, release agents, coating agents, flavors, antioxidants, and the like, which are conventional in the pharmaceutical art. If necessary, a flavor, a preservative, a sweetener and the like may be further added to the pharmaceutical composition.
In one embodiment of the present invention, the aforementioned pharmaceutical formulation may further comprise one or more second therapeutically active agents, said second therapeutically active agents being as described hereinbefore.
The invention also provides application of the compound shown in the general formula (I), (II), (III), (IV) or (V), pharmaceutically acceptable salt, ester or stereoisomer thereof, the pharmaceutical preparation or the pharmaceutical composition in preparing medicines for treating and/or preventing ASK 1-mediated diseases and related diseases.
In some embodiments of the invention, the ASK 1-mediated and related diseases are selected from cardiovascular diseases including, but not limited to, pulmonary hypertension, multiple sclerosis, atherosclerosis, angina pectoris, intermittent claudication syndrome, myocardial infarction, heart failure; selected from pulmonary diseases including but not limited to asthma, chronic obstructive pulmonary disease, bronchitis, and emphysema; selected from metabolic disorders including but not limited to diabetes and its complications, metabolic syndrome, dyslipidemia, obesity, glucose intolerance, hypertension, high serum cholesterol and higher triglycerides; hepatobiliary kidney diseases, including but not limited to diabetic nephropathy, non-alcoholic fatty liver disease, bile acid disorders, primary sclerosing cholangitis, cholesterol stones, fatty liver, cirrhosis, hepatitis, liver failure, cholestasis, cholelithiasis; hyperproliferative diseases include, but are not limited to, gastric cancer, liver cancer, polyposis, colon cancer, breast cancer, pancreatic cancer, esophageal cancer; other diseases, including neurodegenerative diseases, fibrosis-related diseases, stroke, inflammatory bowel diseases, autoimmune disorders.
The invention also provides the application of the compound shown in the general formula (I), (II), (III), (IV) or (V), the pharmaceutically acceptable salt, ester or stereoisomer thereof, the pharmaceutical preparation or the pharmaceutical composition in treating and/or preventing diseases.
The invention also provides the compound shown in the general formula (I), (II), (III), (IV) or (V), and pharmaceutically acceptable salt, ester or stereoisomer thereof, the pharmaceutical preparation or the pharmaceutical composition thereof, and the application thereof in treating and/or preventing ASK1 mediated diseases and related diseases; the ASK1 mediated diseases and related diseases are as described above.
The invention also provides a method for treating diseases, which comprises the step of administering a therapeutically effective amount of the compound shown in the general formula (I), (II), (III), (IV) or (V), the pharmaceutically acceptable salt, the ester or the stereoisomer thereof, the pharmaceutical preparation or the pharmaceutical composition to a patient in need thereof, wherein the diseases are ASK1 mediated diseases and related diseases; the ASK1 mediated diseases and related diseases are as described above.
Definition of
"halogen" as referred to herein means fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine.
The ' oxo ' in the invention means that any C atom in the substituent structure can be oxidized into ' -C (O) -; if containing heteroatoms, the heteroatoms may form oxides, e.g.Can be oxidized intoS is optionally oxidized to S (O) or S (O)2。
"halo" as used herein means that any one of the substituents may be substituted by one or more of the same or different halogens. "halogen" is as defined above.
Said "C" of the present invention1-10Alkyl "refers to a straight or branched chain alkyl group derived from a hydrocarbon containing 1 to 10 carbon atoms with one hydrogen removed from the hydrocarbon moiety, e.g., methyl, ethyl, n-propyl, isopropylN-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, and 1-methyl-2-methylpropyl, and the like. Said "C1-6Alkyl "or" C1-4Alkyl "refers to the above examples containing 1 to 6 or 1 to 4 carbon atoms.
"C" according to the invention2-10Alkynyl "refers to a straight or branched chain alkynyl group having 2 to 10 carbon atoms containing a carbon-carbon triple bond with one hydrogen-derived removed from the alkynyl moiety, such as ethynyl, propynyl, 2-butynyl, 2-pentynyl, 3-pentynyl, 4-methyl-2-pentynyl, 2-hexynyl, 3-hexynyl, and the like. Said "C2-6Alkynyl "refers to the above examples containing 1-6 carbon atoms.
"C" according to the invention2-10Alkenyl "means a straight chain or branched alkenyl group derived from an olefin of 2 to 10 carbon atoms having a carbon-carbon double bond by removing one hydrogen atom, such as vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 1, 3-butadienyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1, 3-pentadienyl, 1, 4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1, 4-hexadienyl, cyclopentenyl, 1, 3-cyclopentadienyl, cyclohexenyl, 1, 4-cyclohexadienyl and the like. Said "C1-6Alkyl "or" C1-4Alkyl "refers to the above examples containing 1 to 6 or 1 to 4 carbon atoms.
"C" according to the invention1-10Alkoxy "means" C "as defined hereinbefore1-10Alkyl "radicals attached to the parent body via an oxygen atom, i.e." C1-10alkyl-O- "groups such as methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, n-pentoxy, neopentoxy, n-hexoxy and the like. Said "C1-6Alkoxy "refers to the above examples containing 1 to 6 carbon atoms, i.e." C1-6An alkyl-O- "group.
And "C1-10Alkoxy radicalSimilarly, the term "C" as used herein1-6Alkylamino "means C1-6alkyl-NH-; "phenoxy" means phenyl-O-; "hydroxy group C1-6Alkyl "means C1-6Each hydrogen on the alkyl group may be substituted with a hydroxyl group; "hydroxy group C1-6Alkoxy "means a hydroxy group C1-6alkyl-O-; ' two (C)1-6Alkyl) amino "means (C)1-6Alkyl radical)2-N-, wherein each C1-6The alkyl groups may be the same or different; "C1-6Alkylthio "means C1-6alkyl-S-; "C1-6Alkylcarbonyl "means C1-6alkyl-C (O) -; "C1-6Alkoxy radical C1-6Alkyl "means C1-6alkyl-O-C1-6An alkyl group; "C1-6Alkylcarbonyloxy "means C1-6alkyl-C (O) -O-; "C1-6Alkylsulfonyl "means C1-6alkyl-S (O)2-;“C1-6Alkylaminosulfonyl "refers to C1-6alkyl-NH-S (O)2-; ' two (C)1-6Alkyl) aminosulfonyl "means (C)1-6Alkyl radical)2-N-S(O)2-, each of which is C1-6The alkyl groups may be the same or different; "C1-6Alkylsulfonamido "means C1-6alkyl-S (O)2-NH-;“C1-6Alkylsulfonyloxy "means C1-6alkyl-S (O)2-O-。
As used herein, the term "halo C1-6Alkyl group "," halogeno C1-6Alkoxy "means C of the group1-6The hydrogen in the alkyl group is substituted with one or more halogens; the "halogen" is as defined above.
The "cycloalkyl", "aryl", "heterocyclyl" and "heteroaryl" in the present invention include a monocyclic ring system and a fused ring system (bicyclic ring system or polycyclic ring system), wherein monocyclic ring means that the ring is present in the form of only one ring, and the fused ring means a polycyclic ring structure formed by connecting two or more rings in parallel, spiro or bridged manner. The fused ring refers to a fused ring structure formed by two or more ring structures sharing two adjacent ring atoms with each other (i.e., sharing one bond). The bridged ring refers to a fused ring structure formed by two or more cyclic structures sharing two non-adjacent ring atoms with each other. The spiro ring refers to a fused ring structure formed by two or more cyclic structures sharing one ring atom with each other. The cycloalkyl group, aryl group, heterocyclic group and heteroaryl group defined by the number of atoms in the present invention include, unless otherwise specified, monocyclic and fused ring structures which can be formed.
The "cycloalkyl" as used herein refers to a monocyclic cycloalkyl, bicyclic cycloalkyl system or polycyclic cycloalkyl system which is saturated or partially saturated and which is not aromatic. The monocyclic cycloalkyl group may be a 3-to 10-membered cycloalkyl group, a 5-to 10-membered cycloalkyl group, a 3-to 8-membered cycloalkyl group, a 3-to 6-membered cycloalkyl group, a 5-to 8-membered cycloalkyl group and the like, preferably a 3-to 8-membered saturated cycloalkyl group, a 3-to 6-membered saturated cycloalkyl group, a 5-to 6-membered saturated cycloalkyl group, examples include, but are not limited to: cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclobutenyl, cyclopentenyl, cyclohexenyl, 1, 4-cyclohexadienyl, cycloheptenyl, 1, 4-cycloheptadienyl, cyclooctenyl, 1, 5-cyclooctadienyl, and the like. The acyclic cycloalkyl group may be a 6-12 membered acyclic heterocycloalkyl group, a 7-10 membered acyclic heterocycloalkyl group, an 8-9 membered acyclic heterocycloalkyl group, representative examples of which include, but are not limited to, bicyclo [3.1.1]Heptane, bicyclo [2.2.1]Heptane, bicyclo [2.2.2]Octane, bicyclo [3.2.2]Nonane, bicyclo [3.3.1]Nonanes and bicyclo [4.2.1]Nonane. Spirocyclic cycloalkyl groups, which may be 6-12-membered spirocyclic groups, 7-11-membered spirocyclic groups, and the like, examples thereof include, but are not limited to: the bridged cycloalkyl group may be 6-12 bridge ring group, 7-11 bridge ring group, examples of which include but are not limited to:
the "3-to 8-membered cycloalkyl" as referred to herein includes, unless otherwise specified, monocyclic and fused ring structures, preferably monocyclic cycloalkyl, which can be formed.
The term "heterocyclic group" as used herein means a non-aromatic cyclic group in which at least one ring carbon atom is replaced by a heteroatom selected from O, S, N, preferably 1 to 3 heteroatoms, and includes carbon, nitrogen and sulfur atoms which may be substituted by oxo.
"Heterocyclyl" refers to a monocyclic heterocyclic group or fused heterocyclic group system that is saturated or partially saturated and has no aromatic character. The monoheterocyclic group may be a 3-12-membered heterocyclic group, a 3-10-membered heterocyclic group, a 3-8-membered saturated heterocyclic group, a 3-6-membered heterocyclic group, a 4-7-membered heterocyclic group, a 5-6-membered oxygen-containing heterocyclic group, a 5-6-membered nitrogen-containing heterocyclic group, a 5-6-membered saturated oxygen-containing heterocyclic group, a 5-6-membered saturated nitrogen-containing heterocyclic group or the like. Examples of mono-heterocyclic groups include, but are not limited to, aziridinyl, oxacyclopropane, thiiranyl, azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydrothienyl, imidazolidinyl, pyrazolidinyl, 1, 2-oxazolidinyl, 1, 3-oxazolidinyl, 1, 2-thiazolidinyl, 1, 3-thiazolidinyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, piperidinyl, piperazinyl, morpholinyl, 1, 4-dioxanyl, 1, 4-oxathianyl; examples of partially saturated heteromonocyclic groups include, but are not limited to, 4, 5-dihydroisoxazolyl, 4, 5-dihydrooxazolyl, 2, 3-dihydrooxazolyl, 3, 4-dihydro-2H-pyrrolyl, 2, 3-dihydro-1H-pyrrolyl, 2, 5-dihydro-1H-imidazolyl, 4, 5-dihydro-1H-pyrazolyl, 4, 5-dihydro-3H-pyrazolyl, 4, 5-dihydrothiazolyl, 2H-pyranyl, 4H-pyranyl, 2H-thiopyranyl, 4H-thiopyranyl, 2,3,4, 5-tetrahydropyridinyl, 2, 5-dihydropyranyl, 2H-pyranyl, 4H-thiopyranyl, 2,3,4, 5-tetrahydropyridinyl, and the like, 1, 2-isooxazinyl, 1, 4-isooxazinyl, or 6H-1, 3-oxazinyl, and the like.
Fused heterocycles include heterocyclo, spiroheterocyclyl, bridged heterocyclo, and may be saturated, partially saturated, or unsaturated, but are not aromatic. The heterocyclic group may be a 6-12 membered fused ring group, a 7-11 membered fused ring group, a 6-10 membered fused ring group, a 6-12 membered saturated fused ring group, a 7-11 membered saturated fused ring group, examples of which include, but are not limited to: 3-azabicyclo [3.10] hexanyl, 3, 6-diazabicyclo [3.2.0] heptane, 3, 8-diazabicyclo [4.2.0] octanyl, 3, 7-diazabicyclo [4.2.0] octanyl, octahydropyrrolo [3,4-c ] pyrrole, octahydropyrrolo [3,4-b ] [1,4] oxazinyl, octahydro-1H-pyrrolo [3,4-c ] pyridine, 2, 3-dihydrobenzofuran-2-yl, 2, 3-dihydrobenzofuranyl-3-yl, indolin-1-yl, indolin-2-yl, indolin-3-yl, 2, 3-dihydrobenzothien-2-yl, octahydro-1H-indolyl, substituted octahydro-1H-indolyl, Octahydrobenzofuranyl.
The spiro heterocyclic group may be a 6-12 membered spiro heterocyclic group, a 7-11 membered saturated spiro heterocyclic group, a 6-12 membered saturated spiro cyclic group, examples of which include, but are not limited to:
examples of said bridged heterocyclic group may be a 6-12 membered bridged heterocyclic group, a 7-11 membered bridged heterocyclic group, a 6-12 membered saturated bridged heterocyclic group, a 7-11 membered saturated bridged heterocyclic group include, but are not limited to:
the 3-to 10-membered heterocyclic group and the 3-to 8-membered heterocyclic group in the present invention include, unless otherwise specified, monocyclic and fused ring structures which can be formed, and a monocyclic heterocyclic group is preferable.
The aryl group refers to an aromatic cyclic group, and comprises a monocyclic ring system, a bicyclic ring system or a polycyclic ring system, and can be 6-14-membered aryl, 6-12-membered aryl, 6-10-membered aryl, 6-8-membered monocyclic aryl and 8-14-membered fused ring aryl, wherein representative examples of the 6-8-membered monocyclic aryl include but are not limited to phenyl and cyclooctenyl; representative examples of 8-14 membered fused ring aryl groups include, but are not limited to, pentalene, naphthalene, phenanthrene.
The term "heteroaryl" as used herein refers to an aromatic cyclic group wherein at least one ring carbon atom is replaced by a heteroatom selected from O, S, N, preferably 1-3 heteroatoms, including the case where carbon, sulfur and nitrogen atoms are oxo, e.g. carbon by C (O), S (O)2And (4) replacing. Heteroaryl includes monoheteroaryl and fused heteroaryl, and may be 5-14 membered heteroaryl, 5-12 membered heteroaryl, 5-10 membered heteroaryl, 5-8 membered heteroaryl, 5-6 membered heteroaryl, representative examples of monoheteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl and triazinyl. Fused heteroaryl refers to a bicyclic or polycyclic ring system fused to a phenyl, cycloalkyl, cycloalkenyl, heterocyclyl, or heteroaryl group. The fused heteroaryl group may be an 8-12 membered heteroaryl group, an 8-10 membered heteroaryl group, a 9-10 membered heteroaryl group, representative examples include, but are not limited to, benzimidazolyl, benzofuranyl, benzothienyl, benzooxadiazolyl, benzothiazolyl, cinnolinyl, 5, 6-dihydroquinolin-2-yl, 5, 6-dihydroisoquinolin-1-yl, indazolyl, indolyl, isoquinolyl, naphthyridinyl, purinyl, quinolyl, 5,6,7, 8-tetrahydroquinolin-2-yl, 5,6,7, 8-tetrahydroquinolyl, 5,6,7, 8-tetrahydroquinolin-4-yl, 5,6,7, 8-tetrahydroisoquinolin-1-yl, 4,5,6, 7-tetrahydro [ c ] do [ c ] yl, and the like][1,2,5]Oxadiazoles and 6, 7-dihydro [ c ]][1,2,5]Oxadiazol-4 (5H) onyl.
The 5-to 14-membered heteroaryl group, the 5-to 12-membered heteroaryl group, and the 5-to 10-membered heteroaryl group according to the present invention include, unless otherwise specified, monocyclic and fused ring structures which can be formed.
In the present invention, "optionally substituted" includes both cases of "substituted" and "unsubstituted".
A "therapeutically effective amount" as referred to herein, refers to an amount of a compound, pharmaceutical formulation, pharmaceutical composition as described above which, when administered to a patient, is capable of at least alleviating the symptoms of the condition in the patient. The actual amount comprising a "therapeutically effective amount" will vary depending on a variety of circumstances, including but not limited to the particular condition being treated, the severity of the condition, the physical and health of the patient, and the route of administration. The appropriate amount can be readily determined by the skilled medical practitioner using methods known in the medical arts.
Advantageous effects of the invention
(1) The compound, the pharmaceutically acceptable salt, the ester or the stereoisomer thereof has excellent ASK1 inhibitory activity, and can treat and/or prevent ASK1 mediated diseases and related diseases;
(2) the compound, the pharmaceutically acceptable salt, the pharmaceutically acceptable ester or the stereoisomer thereof has good pharmacokinetic property, more lasting effect and high bioavailability;
(3) the compound of the invention has simple preparation process, high medicine purity, stable quality and easy large-scale industrial production.
Detailed Description
The technical solutions of the present invention will be described below with reference to specific embodiments, and the described embodiments are only a part of embodiments of the present invention, but not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The abbreviations used in the following experiments have the following meanings:
PE: petroleum ether EA: ethyl acetate DCM: dichloromethane MeOH: methanol
DMF-DMA: n, N-dimethylformamide dimethyl acetal DIEA: n, N-diisopropylethylamine
THF: tetrahydrofuran Pd2(dba)3: tris (dibenzylideneacetone) dipalladium
X-antiphos: (4, 5-bis (diphenylphosphino) -9, 9-dimethylxanthene)
X-phos: 2-dicyclohexylphosphine-2 ', 4 ', 6 ' -triisopropylbiphenyl
EDCI: 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride
HOBt: 1-hydroxybenzotriazoles
The double bond structure appearing in the structure of the compound of the present inventionRepresents that the compound is a single compound with an unidentified cis-trans configuration or a mixture of cis-trans compounds.
Preparation examples
EXAMPLE 17 preparation of- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one (Compound 1)
1.1 preparation of 7-nitro-3, 4-dihydroisoquinolin-1 (2H) -one
Potassium nitrate (3.71g,36.7mmol) was added to concentrated sulfuric acid (27mL), and 3, 4-dihydroisoquinolin-1 (2H) -one (4.50g,30.6mmol) was added thereto at 0 ℃ to react for 2 hours. The reaction solution was poured into ice water, filtered under suction, and the obtained solid was washed with water and dried to obtain the objective compound (4.00g, yield 68.0%).
Preparation of 1.2, 6-bromopyridine carbohydrazide
Methyl 6-bromopicolinate (5.00g,23.1mmol) was dissolved in methanol (100mL), and hydrazine hydrate (12.47g,249.1mmol) was added to the solution to react for 2 hours. After concentration, ethyl acetate (10mL) and methyl t-butyl ether (100mL) were added, followed by suction filtration and drying of the solid to obtain the objective compound (4.00g, yield 80.0%).
1.3 preparation of (E) -N' - (6-bromopicolinoyl) -N, N-dimethylformylhydrazone amide
6-Bromopyridinecarboxhydrazide (4.00g,18.5mmol) was added to DMF-DMA (15 mL). The reaction was stirred at 80 ℃ for 16 hours, concentrated, added with n-heptane (100mL) and ethyl acetate (10mL), stirred for 1 hour, filtered with suction, and the solid was dried to give the title compound (5.00g, 99.6% yield).
Preparation of 4, 2-bromo-6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridine
(E) -N' - (6-bromopicolinoyl) -N, N-dimethylformylhydrazone amide (5.00g,18.45mmol) and acetic acid (18.5mL) were added to acetonitrile (74mL), isopropylamine (7.60mL,92.25mmol) was added dropwise, the mixture was heated to 95 ℃ for 16 hours, concentrated, and purified by silica gel column chromatography (PE: EA ═ 1:1) to obtain the objective compound (4.65g, yield: 94.3%).
1.5 preparation of 7-amino-3, 4-dihydroisoquinolin-1 (2H) -one
7-Nitro-3, 4-dihydroisoquinoline-1 (2H) -one (1.88g,9.8mmol) and Pd/C (190mg) were added to methanol (50mL), hydrogenated for 3 hours, filtered with suction, and the filtrate was concentrated to give the title compound (1.57g, 98.7% yield).
Preparation of 6,7- ((2-cyclopropyl-2-oxoethyl) amino) -3, 4-dihydroisoquinolin-1 (2H) -one
7-amino-3, 4-dihydroisoquinolin-1 (2H) -one (1.20g,7.4mmol), 2-bromo-1-cyclopropylethan-1-one (1.32g,8.1mmol), DIEA (1.91g,14.8mmol) were added to toluene (20mL), stirred at 95 ℃ for 6 hours, concentrated, and purified by silica gel column chromatography (PE: EA ═ 1:1) to give the title compound (1.50g, 83.0% yield).
1.7 preparation of N- (2-cyclopropyl-2-oxoethyl) -N- (1-oxo-1, 2,3, 4-tetrahydroisoquinolin-7-yl) carboxamide
7- ((2-cyclopropyl-2-oxoethyl) amino) -3, 4-dihydroisoquinolin-1 (2H) -one (1.50g,6.1mmol) was dissolved in dichloromethane (5mL) for further use.
Acetic anhydride (2.49g,24.4mmol) was added dropwise to formic acid (1mL) at 0 deg.C, and stirring was continued at 0 deg.C after the addition was complete. After 0.5 hours, a solution of 7- ((2-cyclopropyl-2-oxoethyl) amino) -3, 4-dihydroisoquinolin-1 (2H) -one in dichloromethane was slowly added dropwise to the system and reacted for 2 hours. The pH was adjusted to 8 with saturated sodium hydroxide solution, extracted with dichloromethane (100mL) saturated sodium chloride solution (80mL), and the organic phase was concentrated to 30mL and used directly in the next step.
1.8 preparation of 7- (4-cyclopropyl-1H-imidazol-1-yl) -3, 4-dihydroisoquinolin-1 (2H) -one
The crude N- (2-cyclopropyl-2-oxoethyl) -N- (1-oxo-1, 2,3, 4-tetrahydroisoquinolin-7-yl) carboxamide solution obtained in the previous step was added to glacial acetic acid (20mL), rotary evaporated to no DCM, and ammonium acetate (1.88g,24.4mmol) was added. The reaction was carried out at 110 ℃ for 16 hours. Adjusting pH to 8-9 with saturated sodium hydroxide solution, adding EA (200mL) for extraction, washing organic phase with saturated sodium chloride solution (150mL), drying with anhydrous sodium sulfate, and concentrating to obtain solid. EA (20mL) was added to the solid, stirred for 0.5h, filtered with suction, and the solid was dried to give the title compound (1.40g, 90.6% overall yield over two steps).
Preparation of 9, 7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one
7- (4-cyclopropyl-1H-imidazol-1-yl) -3, 4-dihydroisoquinolin-1 (2H) -one (500mg,1.97mmol), 2-bromo-6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridine (579mg,2.17mmol), cesium carbonate (1.28g,3.94mmol), Pd2(dba)3(92mg,0.10mmol), X-antiphos (116mg,0.20mmol) was added to 1,4-Dioxane (300mL) was stirred under nitrogen at 80 ℃ for 16h, concentrated and purified by silica gel column chromatography (DCM: MeOH ═ 20:1) to give the title compound (150mg, 17.3% yield).
The molecular formula is as follows: c25H25N7O molecular weight: 439.2 LC-MS (M/e): 440.1(M + H)+)
1H NMR(CD3OD):8.85(s,1H),8.18(d,J=2.4Hz 1H),8.12-8.00(m,3H),8.00-7.93(m,1H),7.78-7.71(m,1H),7.55-7.45(m,1H),7.34(s,1H),5.60-5.45(m,1H),4.38-4.25(m,2H),3.30-3.22(m,2H),1.95-1.80(m,1H),1.65-1.55(m,6H),0.95-0.85(m,2H),0.75-0.65(m,2H).
Example 27 preparation of- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one (Compound 2)
2.1 preparation of 2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -7-nitroisoquinolin-1 (2H) -one
2-bromo-6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridine (2.55g,9.6mmol), 7-nitro-3, 4-dihydroisoquinolin-1 (2H) -one (1.84g,9.6mmol), cesium carbonate (6.26g,19.2mmol), Pd2(dba)3(440mg,0.48mmol), X-antphos (556mg,0.96mmol) was added to 1, 4-dioxane (100mL), stirred at 80 ℃ under nitrogen for 16 hours, concentrated, and purified by silica gel column chromatography (PE: EA ═ 1:1) to give the title compound (450mg, 12.5% yield).
2.2 preparation of 7-amino-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one
2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -7-nitroisoquinolin-1 (2H) -one (450mg,1.2mmol) was dissolved in THF (10mL) and methanol (10mL), hydrogenated for 2 hours, filtered with suction, and the filtrate was concentrated to give the title compound (400mg, 96.2% yield).
Preparation of 3,7- ((2-cyclopropyl-2-oxoethyl) amino) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one
7-amino-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one (345mg,1.0mmol), 2-bromo-1-cyclopropyleth-1-one (196mg,1.2mmol), DIEA (284mg,2.2mmol) was added to toluene (10mL), the reaction was stirred at 95 ℃ for 16 hours, concentrated, and purified by silica gel column chromatography (DCM: MeOH ═ 20:1) to give the title compound (350mg, 81.7% yield).
2.4 preparation of N- (2-cyclopropyl-2-oxoethyl) -N- (2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -1-oxo-1, 2-dihydroisoquinolin-7-yl) carboxamide
7- ((2-cyclopropyl-2-oxoethyl) amino) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one (350mg,0.82mmol) was dissolved in dichloromethane (5mL) for use.
Acetic anhydride (335mg,3.28mmol) was added dropwise to formic acid (1mL) at 0 deg.C, and stirring was continued at 0 deg.C after the addition was complete. After 0.5 hour, a dichloromethane solution of 7- ((2-cyclopropyl-2-oxoethyl) amino) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one was slowly added dropwise to the system and reacted for 2 hours. The pH was adjusted to 8 with saturated sodium hydroxide solution, extracted with dichloromethane (20mL) saturated sodium chloride solution (15mL) and the organic phase was concentrated and used directly in the next step.
Preparation of 7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one
The crude N- (2-cyclopropyl-2-oxoethyl) -N- (2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -1-oxo-1, 2-dihydroisoquinolin-7-yl) carboxamide (0.82mmol) obtained in the above step was dissolved in glacial acetic acid (6mL), and ammonium acetate (253mg,3.28mmol) was added. The reaction was carried out at 110 ℃ for 16 hours. The pH was adjusted to 8 with saturated sodium hydroxide solution, dichloromethane (50mL) was added and water (40mL) was added for extraction, the organic phase was concentrated, and after silica gel column chromatography (DCM: MeOH ═ 20:1), the title compound (50mg, 14.0% total yield over two steps) was prepared under high pressure.
The molecular formula is as follows: c25H23N7O; molecular weight: 437.2, respectively; LC-MS (M/e): 438.3(M + H)+)。
1H NMR(CD3OD):8.90(s,1H),8.45(d,J=2.4Hz,1H),8.25-8.18(m,2H),8.18-8.10(m,1H),8.10-7.90(m,2H),7.90-7.75(m,2H),7.45-7.43(m,1H),6.86(d,J=7.6Hz,1H),5.55-5.38(m,1H),2.00-1.89(m,1H),1.65-1.52(m,6H),0.93-0.90(m,2H),0.82-0.71(m,2H).
Example 2 preparation of 17- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one (Compound 2)
Preparation of 2-1.1 methyl 2- (2- (dimethylamino) vinyl) -5-nitrobenzoate
Methyl 2-methyl-5-nitrobenzoate (7.0g,35.9mmol) was dissolved in 1-tert-butoxy-N, N' -tetramethylmethanediamine (9.4g,53.9mmol), reacted at 115 ℃ for 2 hours to precipitate a solid, filtered, the cake was then washed with a mixed solvent of petroleum ether and ethyl acetate (60mL, petroleum ether: ethyl acetate ═ 6:1), filtered, and the cake was dried to obtain the objective product (8.1g, yield: 90.2%).
Preparation of 2-1.2- (2, 4-dimethoxybenzyl) -7-nitroisoquinolin-1 (2H) -one
Methyl 2- (2- (dimethylamino) vinyl) -5-nitrobenzoate (8.19g,32.7mmol) and 2, 4-dimethoxybenzylamine (7.6g,45.4mmol) were added to a toluene (80mL) solution, heated to 125 ℃, reacted for 2.5 hours, a solid was precipitated, cooled to 25 ℃, filtered, and the filter cake was then slurry-washed with a mixed solvent of petroleum ether and ethyl acetate (100mL, petroleum ether: ethyl acetate ═ 2:1), filtered, and the filter cake was dried to obtain the objective product (9.0g, yield: 81.6%).
Preparation of 2-1.3.7-amino-2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one
2- (2, 4-Dimethoxybenzyl) -7-nitroisoquinolin-1 (2H) -one (8.4g,24.7mmol), zinc powder (8.1g,123.8mmol), ammonium chloride (7.9g,147.7mmol) were added to methanol (100mL) and water (100mL), reacted at 80 ℃ for 4 hours, filtered, the filtrate was added with water (100mL), extracted with dichloromethane (300 mL. times.3), the organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the objective compound (7.4g, yield: 96.6%).
Preparation of 2-1.4.7- ((2-cyclopropyl-2-oxoethyl) amino) -2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one
7-amino-2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one (5.0g,16.1mmol), 2-bromo-1-cyclopropylethyl-1-one (3.1g,19.0mmol), N-diisopropylethylamine (4.2g,32.6mmol) were sequentially added to a mixed solvent of toluene (15mL), tetrahydrofuran (15mL) and dichloromethane (30mL), heated to 80 deg.C, reacted for 5 hours, spin-dried, and the residue was subjected to column chromatography (petroleum ether: ethyl acetate: 5:1-1:1) to obtain the objective compound (3.6g, yield: 57.0%).
Preparation of N- (2-cyclopropyl-2-oxoethyl) -N- (2- (2, 4-dimethoxybenzyl) -1-oxo-1, 2-dihydroisoquinolin-7-yl) carboxamide
Acetic anhydride (5.2g,12.7mmol) was dropped into formic acid (30mL) at 0 ℃ to react for 0.5 hour, a solution of 7- ((2-cyclopropyl-2-oxoethyl) amino) -2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one (5.0g,12.7mmol) in dichloromethane (30mL) was dropped into the reaction system to react at 0 ℃ for 16 hours, PH was adjusted to 7 with 1N sodium hydroxide solution, dichloromethane (400mL × 2) was extracted, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and rotary-dried to obtain a crude product (5.0 g).
Preparation of 2-1.6.7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one
N- (2-cyclopropyl-2-oxoethyl) -N- (2- (2, 4-dimethoxybenzyl) -1-oxo-1, 2-dihydroisoquinolin-7-yl) carboxamide (5.0g, crude) and ammonium acetate (7.5g,97.3mmol) were dissolved in acetic acid (30mL), heated to 105 ℃, reacted for 16 hours, 0 ℃, adjusted pH 7 with sodium hydroxide solution (2M), extracted with dichloromethane (150 mL. times.3), the combined organic phases were dried over anhydrous sodium sulfate, filtered, and spin-dried to give crude (5.1 g).
Preparation of 2-1.7.7- (4-cyclopropyl-1H-imidazol-1-yl) isoquinolin-1 (2H) -one
7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one (5.1g, crude) was dissolved in trifluoroacetic acid (30mL), heated to 90 ℃ for 3 hours, concentrated, slurried with ethyl acetate (50mL), filtered, and the solid was dried to give the title compound (2.2g, three-step yield: 68.9%).
Preparation of 2-1.8.7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one
7- (4-cyclopropyl-1H-imidazol-1-yl) isoquinolin-1 (2H) -one (1.0g,3.98mmol), 2-bromo-6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridine (900mg, 3.37mmol), 4, 5-bis diphenylphosphino-9, 9-dimethylxanthene (129mg, 0.22mmol), tris (dibenzylideneacetone) dipalladium (204mg, 0.22mmol) and cesium carbonate (2.4g, 7.37mmol) were dissolved in 1, 4-dioxane (70mL) and reacted at 105 ℃ for 16 hours under nitrogen. Concentration and reverse phase column chromatography (acetonitrile/water 0-50%) to give crude product, slurried with methanol (5mL) and methyl tert-butyl ether (20mL), filtered and the filter cake dried to give the title compound (400mg, 27.1% yield).
Molecular formula C25H23N7O molecular weight 437.51 LC-MS (M/e):438.2(M + H)+)
1H-NMR(400MHz,CDCl3)δ:8.46(s,1H),8.39(s,1H),8.32-8.36(m,1H),8.01-8.07(m,1H),7.86(d,J=1.2Hz,1H),7.66-7.74(m,3H),7.16(d,J=0.8Hz,1H),6.68(d,J=8Hz,1H),5.44-5.51(m,1H),1.91-1.96(m,1H),1.53(d,J=11.2Hz,6H),0.80-0.93(m,4H).
EXAMPLE 37 preparation of- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxyisoquinolin-1 (2H) -one (Compound 3)
Preparation of 3.1, 2-methyl-4, 5-dinitrobenzoic acid
Dissolving 2-methyl-4-nitrobenzoic acid (10.0g, 55.2mmol) in concentrated sulfuric acid (60mL), adding a solution of potassium nitrate (8.4g, 83.2mmol) in concentrated sulfuric acid (40mL) dropwise to the reaction mixture, pouring into ice water at 25 ℃, for 16 hours, precipitating a solid, and drying in vacuum to obtain the target compound 9g, yield: 72 percent.
Preparation of 3, 4-methoxy-2-methyl-5-nitrobenzoic acid
2-methyl-4, 5-dinitrobenzoic acid (9g,39.8mmol) was added in portions to a solution of potassium hydroxide (11g,196.4mmol) in methanol (200mL), heated to 70 ℃ for 3 hours, adjusted in pH 3-4 with 2N hydrochloric acid, and a solid was precipitated, filtered, and dried in vacuo to give the objective compound (7g, yield: 83.3%).
Preparation of methyl 3, 4-methoxy-2-methyl-5-nitrobenzoate
4-methoxy-2-methyl-5-nitrobenzoic acid (7.0g,33.2mmol) was dissolved in methanol (100mL), thionyl chloride (8.5g,71.4mmol) was added at 0 ℃, heated to 70 ℃, for 16 hours, spin-dried, added with 200mL of ethyl acetate, washed with a saturated sodium bicarbonate solution, spin-dried, and column-chromatographed (petroleum ether: ethyl acetate ═ 8:1) to give the title compound (6.0g, yield: 80%).
3.4 preparation of methyl (E) -2- (2- (dimethylamino) ethenyl) -4-methoxy-5-nitrobenzoate
Methyl 4-methoxy-2-methyl-5-nitrobenzoate (5.0g,22.2mmol), 1-tert-butoxy-N, N' -tetramethylmethanediamine (5.8g,33.3mmol) were heated to 115 ℃ for 3 hours, cooled to 25 ℃, added with a mixed solvent of petroleum ether and ethyl acetate (6: 1) (50mL), filtered, and the solid was dried under vacuum to give the objective compound 5.5g, yield: 88.7%.
Preparation of 2- (2, 4-dimethoxybenzyl) -6-methoxy-7-nitroisoquinolin-1 (2H) -one
Methyl (E) -2- (2- (dimethylamino) vinyl) -4-methoxy-5-nitrobenzoate (5.0g,17.8mmol), 2, 4-dimethoxybenzylamine (4.5g,26.9mmol) were dissolved in toluene (100mL), heated to 110 ℃, reacted for 16 hours, the solvent was dried, a mixed solvent of petroleum ether and ethyl acetate 2:1 (80mL) was added, filtered, and the solid was dried in vacuo to give the objective compound 5.5g, yield: 91.1%.
Preparation of 6, 6-methoxy-7-nitroisoquinolin-1 (2H) -one
2- (2, 4-Dimethoxybenzyl) -6-methoxy-7-nitroisoquinolin-1 (2H) -one (5.5g,14.9mmol) was dissolved in trifluoroacetic acid (50mL), heated to 85 deg.C for 3 hours, the solvent was dried, methanol (50mL) was added, ethyl acetate (60mL) was added, filtered, and the solid was dried under vacuum to give the title compound (3.1g, yield: 93.9%).
3.7 preparation of methyl 6- (6-methoxy-7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinate
6-methoxy-7-nitroisoquinolin-1 (2H) -one (2.8g,12.7mmol), methyl 6-bromopicolinate (4.1g,18.9mmol), cuprous iodide (0.24g,1.26mmol), potassium phosphate (5.4g,25.5mmol), tetramethylethylenediamine (0.3g,2.58mmol), toluene (100mL), heated to 110 deg.C for 16 hours, methanol: a mixed solvent (100mL) of 9:15 methylene chloride was filtered, and the solid was dried in vacuo to give 3.0g of the objective compound in 66.7% yield.
3.8 preparation of 6- (6-methoxy-7-nitro-1-oxoisoquinolin-2 (1H) -yl) pyridinecarbohydrazide
Methyl 6- (6-methoxy-7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinate (600mg,1.7mmol) was dissolved in methanol (30mL), hydrazine monohydrate solution (3mL) was added, heated to 65 ℃ for 16H, spun dry, and the residue was used directly in the next step.
3.9 preparation of (E) -N' - (6- (6-methoxy-7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinoyl) -N, N-dimethylformamidine
6- (6-methoxy-7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinohydrazide (crude, 1.7mmol), N, N-dimethylformamide dimethyl acetal (20mL) was heated to 90 ℃ and reacted for 16 hours. Spin dry and the residue was used directly in the next step.
3.10 preparation of 2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxy-7-nitroisoquinolin-1 (2H) -one
(E) -N' - (6- (6-methoxy-7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinoyl) -N, N-dimethylformamidine (crude, 1.7mmol) was dissolved in a mixed solvent of acetic acid (1mL) and acetonitrile (4mL), isopropylamine (0.5g,8.5mmol) was added, heated to 70 ℃ for 16 hours, spin-dried, and column chromatography of the residue (dichloromethane: methanol ═ 20:1) gave the title compound (0.48g, three-step yield: 69.6%).
Preparation of 11, 7-amino-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxyisoquinolin-1 (2H) -one
2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxy-7-nitroisoquinolin-1 (2H) -one (0.48g,1.2mmol) was added to methanol (300mL), stannous chloride (1.1g,5.8mmol) and hydrochloric acid (1mL) were added, heated to 70 ℃ for 16 hours, a saturated sodium bicarbonate solution was added, filtered, the filtrate was spun dry, and the residue was subjected to column chromatography (dichloromethane: methanol ═ 30:1) to give the objective compound (0.25g, yield: 56.8%).
Preparation of 12, 7- ((2-cyclopropyl-2-oxoethyl) amino) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxyisoquinolin-1 (2H) -one
7-amino-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxyiso-1 (2H) -one (0.25g,0.66mmol), 2-bromo-1-cyclopropylethyl-1-one (0.16g,0.98mmol) was dissolved in toluene (30mL), N-diisopropylethylamine (0.17g,1.3mmol) was added, heated to 95 ℃ for 16 hours, spun-dried, and the residue was subjected to column chromatography (dichloromethane: methanol ═ 30:1) to give the objective compound (95mg, yield: 31.7%).
3.13 preparation of N- (2-cyclopropyl-2-oxoethyl) -N- (2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxy-1-oxo-1, 2-dihydroisoquinolin-7-yl) carboxamide
7- ((2-cyclopropyl-2-oxoethyl) amino) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxyisoquinolin-1 (2H) -one (95mg,0.21mmol) was dissolved in acetic acid (3mL), acetic anhydride (43mg,0.42mmol) was added, heated to 25 ℃ for 16H, adjusted to pH 8-9 with 2N sodium hydroxide solution, extracted with dichloromethane (30 mL. times.2), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, spun dry and the residue was used directly in the next step.
3.14 preparation of 7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxyisoquinolin-1 (2H) -one
N- (2-cyclopropyl-2-oxoethyl) -N- (2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -6-methoxy-1-oxo-1, 2-dihydroisoquinolin-7-yl) carboxamide (crude, 0.21mmol) was dissolved in acetic acid (5mL), ammonium acetate (160mg,2.1mmol) was added, heating was carried out to 110 ℃, for 16 hours, spin-dried, sodium bicarbonate solution (10mL) was added to adjust pH to 8-9, dichloromethane (20mL × 3) was extracted, the organic phases were combined, TLC separation (dichloromethane: methanol: 20:1) was carried out to obtain the objective compound 46mg, yield: 47.4 percent.
Molecular formula C26H25N7O2Molecular weight 467.53 LC-MS (M/e):468.2(M + H)+)
1H-NMR(400MHz,d-DMSO)δ:8.92(s,1H),8.15-8.19(m,2H),8.11(s,1H),7.95(dd,J=7.2Hz,2.0Hz,1H),7.86(d,J=7.6Hz,1H),7.81(s,1H),7.50(s,1H),7.26(s,1H),6.82(d,J=7.6Hz,1H),5.27-5.30(m,1H),3.97(s,3H),1.82-1.89(m,1H),1.47(d,J=6.4Hz,6H),0.76-0.81(m,2H),0.67-0.70(m,2H).
Example 47 preparation of- (4-cyclopropyl-1H-imidazol-1-yl) -4-fluoro-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one (Compound 4)
4.1 Synthesis of 7- (4-cyclopropyl-1H-imidazol-1-yl) -4-fluoro-3-hydroxy-3, 4-dihydroisoquinolin-1 (2H) -one
The compound 7- (4-cyclopropyl-1H-imidazol-1-yl) isoquinolin-1 (2H) -one (502mg,2mmol), 1-chloromethyl-4-fluoro-1, 4-diazobicyclo 2.2.2 octane bis (tetrafluoroborate) salt (1.42g, 4mmol) was dissolved in acetonitrile (30mL), and water (0.5mL) was added to conduct a reaction under reflux for 5 hours. The reaction mixture was concentrated, water (100mL) was added thereto, the mixture was washed with dichloromethane three times (100mL × 3), the aqueous phase was concentrated, a mixed solvent of dichloromethane and methanol (dichloromethane: methanol ═ 20:2) was added to the residue, the mixture was filtered with suction, and the filtrate was concentrated for use.
4.2 Synthesis of 7- (4-cyclopropyl-1H-imidazol-1-yl) -4-fluoroisoquinolin-1 (2H) -one
The crude product obtained in the above step was dissolved in methylene chloride (10mL), and methanesulfonic acid (1.25g,13mmol) was added at 0 ℃ to react at 10 ℃ for 3 hours. Concentration and reverse phase column chromatography (0-35% MeOH) of the residue afforded 100mg of the title compound in 18.6% yield over two steps.
The molecular formula is as follows: c15H12FN3O molecular weight: 269.3 LC-MS (M/e):270.1(M+H)
1H-NMR(400MHz,CD3OD)δ:9.40(brs,1H),8.55(s,1H),8.12-8.15(m,1H),8.05-8.08(m,1H),7.92(brs,1H),7.37(d,J=5.6HZ,1H),2.00-2.10(m,1H),1.13-1.16(m,2H),0.92-0.94(m,2H).
4.3 Synthesis of 7- (4-cyclopropyl-1H-imidazol-1-yl) -4-fluoro-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one
The compound 7- (4-cyclopropyl-1H-imidazol-1-yl) -4-fluoroisoquinolin-1 (2H) -one (100mg,0.37mmol), 2-bromo-6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridine (99mg,0.37mmol), 4, 5-bis diphenylphosphine-9, 9-dimethylxanthene (20mg, 20%), tris (dibenzylideneacetone) dipalladium (10mg, 10%) and cesium carbonate (362mg,1.11mmol) were dissolved in 1, 4-dioxane (10mL) and reacted at 110 ℃ for 15 hours under nitrogen. The reaction mixture was concentrated, water (100mL) was added thereto, methylene chloride was extracted three times (100mL × 3), the organic phase was concentrated and dried, and the residue was subjected to silica gel column chromatography (methylene chloride: methanol ═ 20:1) and reverse phase column chromatography (0-40% methanol) in this order to obtain 15mg of the objective compound with a yield of 8.9%.
The molecular formula is as follows: c25H22FN7O molecular weight: 455.5 LC-MS (M/e):456.2(M + H)
1H-NMR(400MHz,CD3OD)δ:9.37(s,1H),8.92(s,1H),8.70(s,1H),8.19-8.24(m,3H),8.10-8.16(m,3H),7.93(s,1H),5.45-5.49(m,1H),2.00-2.10(m,1H),1.58-1.61(m,6H),1.12-1.21(s,2H),0.91-1.00(s,2H).
Example preparation of 57- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3-methylisoquinolin-1 (2H) -one (Compound 5)
5.1 preparation of methyl 6- (7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinate
7-Nitroisoquinolin-1 (2H) -one (3g,15.8mmol), methyl 6-bromopicolinate (4.4g,20.4mmol), potassium phosphate (6.7g,31.6mmol), tetramethylethylenediamine (90mg,0.79mmol) and cuprous iodide (0.15g,0.79mmol) were added to toluene (150mL) and the reaction stirred at 100 deg.C for 16 hours under nitrogen. Cooled to 20 ℃, concentrated to dryness, washed with water (200mL), filtered, the filter cake washed with methanol and dried to give the title compound (1.6g, yield: 31.2%).
5.2 preparation of methyl 6- (3-methyl-7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinate
Methyl 6- (7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinate (1.5g,4.61mmol), potassium methyltrifluoroborate (1.7g,13.9mmol), silver hexafluoroantimonate (0.32g,0.93mmol), silver oxide (1.6g,6.91mmol), dichloro (pentamethylcyclopentadienyl) rhodium dimer (0.15g,0.24mmol) were dissolved in 1, 2-dichloroethane (100mL), nitrogen protected, heated to 80 ℃ and stirred for reaction for 16 hours. Potassium methyltrifluoroborate (1.7g,13.9mmol), silver hexafluoroantimonate (0.32g,0.93mmol), and dichloro (pentamethylcyclopentadienyl) rhodium dimer (0.15g,0.24mmol) were added, and the reaction was continued with stirring for 16 hours. Filtration and concentration of the filtrate were carried out, and purification by silica gel column chromatography (ethyl acetate: petroleum ether ═ 1:1) was carried out to give the objective compound (0.25g, yield: 16.0%) and methyl 6- (7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinate (1.3g) was recovered.
5.3 preparation of methyl 6- (7-amino-3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinate
Methyl 6- (3-methyl-7-nitro-1-oxoisoquinolin-2 (1H) -yl) picolinate (0.63g,1.86mmol) was dissolved in methanol (10mL), triethylamine (1mL) and Pd/C (0.3g) were added, and the reaction was stirred under hydrogen pressure at 20 ℃ for 3 hours. Filtration and concentration of the filtrate, and purification of the crude product by silica gel column chromatography (dichloromethane: methanol ═ 20:1) gave the title compound (0.38g, yield 66.0%).
Preparation of methyl 6- (7- ((2-cyclopropyl-2-oxoethyl) amino) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinate
Methyl 6- (7-amino-3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinate (0.37g,1.2mmol) and DIEA (0.31g,2.4mmol) were dissolved in toluene (10mL), 2-bromo-1-cyclopropyleth-1-one (0.24g,1.5mmol) was added, the reaction was stirred under nitrogen protection at 95 ℃ for 16 hours, concentrated, and the resulting crude product was purified by silica gel column chromatography (dichloromethane: methanol ═ 20:1) to give the objective compound (0.15g, yield 32.0%), and methyl 6- (7-amino-3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinate (0.22g) was recovered.
5.5 preparation of methyl 6- (7- (N- (2-cyclopropyl-2-oxoethyl) carboxamido) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinate
Acetic anhydride (0.37g,3.62mmol) was dissolved in formic acid (5mL), and the reaction was stirred at 20 ℃ for 30 minutes, methyl 6- (7- ((2-cyclopropyl-2-oxoethyl) amino) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinate (0.28g,0.72mmol) was added, and the reaction was stirred at 25 ℃ for 16 hours. Saturated aqueous sodium bicarbonate was added to neutralize the pH to 7. Extraction was performed with ethyl acetate (200 mL. times.5), and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give the crude target compound (0.3 g).
5.6 preparation of methyl 6- (7- (4-cyclopropyl-1H-imidazol-1-yl) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinate
The crude methyl 6- (7- (N- (2-cyclopropyl-2-oxoethyl) carboxamido) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinate (0.3g) was dissolved in acetic acid, ammonium acetate (0.3g,3.89mmol) was added, the reaction was stirred under nitrogen at 110 ℃ for 16 hours and concentrated to give the crude product which was isolated and purified by medium pressure to give the title compound (0.2g, 70.0% yield over two steps).
Preparation of 6- (7- (4-cyclopropyl-1H-imidazol-1-yl) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) pyridine carboxylic acid hydrazide
Methyl 6- (7- (4-cyclopropyl-1H-imidazol-1-yl) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinate (0.2g,0.5mmol) was dissolved in methanol (5mL), 85% hydrazine hydrate (2mL) was added and the reaction stirred at 20 ℃ for 16H. And concentrating, and directly using the obtained crude product for the next reaction.
Preparation of N' - (6- (7- (4-cyclopropyl-1H-imidazol-1-yl) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinoyl) -N, N-dimethylcarbohydrazide
The crude 6- (7- (4-cyclopropyl-1H-imidazol-1-yl) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) pyridine carbohydrazide obtained in the previous step was dissolved in DMF-DMA (5 mL). The reaction was stirred for 16 hours while heating to 80 ℃. Concentration and washing the crude product with methyl tert-butyl ether to give crude target compound (92 mg).
Preparation of 9, 7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3-methylisoquinolin-1 (2H) -one
Crude N' - (6- (7- (4-cyclopropyl-1H-imidazol-1-yl) -3-methyl-1-oxoisoquinolin-2 (1H) -yl) picolinoyl) -N, N-dimethylformylhydrazine (92mg) was dissolved in a mixed solvent of acetic acid (1mL) and acetonitrile (4mL), isopropylamine (60mg,1mmol) was added, and the mixture was heated to 95 ℃ for 16 hours. Concentration and the resulting crude product was purified by preparative high pressure to give the objective compound (11mg, three-step yield: 4.9%).
The molecular formula is as follows: c26H25N7O molecular weight: 451.5 LC-MS (M/e): 452.3(M + H)+)
1H NMR(CD3OD):8.85(s,1H),8.27-8.34(m,3H),8.13(s,1H),7.94-7.97(m,1H),7.79(d,J=8.4Hz 1H),7.68(dd,J1=7.6Hz,J2=1.2Hz,1H),7.42(s,1H),6.75(s,1H),5.37-5.42(m,1H),2.11(s,3H),1.88-1.95(m,1H),1.45-1.55(m,6H),0.88-0.92(m,2H),0.76-0.80(m,2H)。
Example 66 preparation of (4-cyclopropyl-1H-imidazol-1-yl) -3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) quinazolin-4 (3H) -one (Compound 6)
Preparation of 1, 5-bromo-N- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -2-nitrobenzamide
5-bromo-2-nitrobenzoic acid (3.31g,13.5mmol), 6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-amine (3.0g,14.8mmol), EDCI (5.15g,26.9mmol), DMAP (327mg,2.7mmol) were added to pyridine (30mL) and reacted at 35 ℃ for 40 hours. Dichloromethane (20mL) was added by evaporation to dryness, and the title compound (1.68g, yield: 28.9%) was obtained by suction filtration.
Preparation of 2, 2-amino-5-bromo-N- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) benzamide
5-bromo-N- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -2-nitrobenzamide (1.66g,3.8mmol), iron powder (1.1g,19.6mmol), ammonium chloride (610mg,11.4mmol), and water (6mL) were added to isopropanol (24mL), stirred at 80 ℃ for 16 hours, methanol (20mL), dichloromethane (20mL) were added, the mixture was sonicated, filtered, and the filtrate was evaporated to dryness to give a crude product of the objective compound (2.0 g).
Preparation of 3, 6-bromo-3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) quinazolin-4 (3H) -one
The crude 2-amino-5-bromo-N- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) benzamide (1.55g) was added to triethyl orthoformate (20mL), reacted at 143 ℃ for 2 hours, cooled to precipitate a solid, and filtered to obtain the crude target compound (1.75 g).
Preparation of tert-butyl (3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -4-oxo-3, 4-dihydroquinazolin-6-yl) carbamate
Crude 6-bromo-3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) quinazolin-4 (3H) -one (1.75g), palladium acetate (83mg,0.34mmol), xanthphos (393mg,0.68mmol), cesium carbonate (2.76g,8.5mmol), tert-butyl carbamate (597mg,5.1mmol) were added to 1, 4-dioxane (15mL), reacted under nitrogen at 100 ℃ for 16 hours, concentrated to dryness, and subjected to silica gel column chromatography (eluent methanol: dichloromethane: 1:25) to give the target compound (950mg, three-step overall yield: 55.9%).
Preparation of 5, 6-amino-3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) quinazolin-4 (3H) -one
Tert-butyl (3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -4-oxo-3, 4-dihydroquinazolin-6-yl) carbamate (920mg,2.1mmol), trifluoroacetic acid (2mL) was added to dichloromethane (6mL), reacted at 12 ℃ for 3 hours, concentrated to dryness, and subjected to silica gel column chromatography (eluent methanol: dichloromethane ═ 1:20) to obtain the objective compound (555mg, yield: 76%).
6.6 preparation of 6- ((2-cyclopropyl-2-oxoethyl) amino) -3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) quinazolin-4 (3H) -one
6-amino-3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) quinazolin-4 (3H) -one (480mg,1.38mmol), 1-cyclopropyl-2-bromoethanone (225mg,1.38mmol), DIEA (356mg,2.76mmol) was added to toluene (18mL), reacted at 90 ℃ for 6 hours, concentrated to dryness, and passed through a silica gel column (eluent methanol: dichloromethane ═ 1:25) to give the title compound (145mg, yield: 24.5%).
Preparation of N- (2-cyclopropyl-2-oxoethyl) -N- (3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -4-oxo-3, 4-dihydroquinazolin-6-yl) carboxamide
Acetic anhydride (138mg,1.35mmol) was diluted with dichloromethane (1mL), added dropwise to formic acid (2mL) at 0 ℃, stirred at 0 ℃ for 0.5H, 6- ((2-cyclopropyl-2-oxoethyl) amino) -3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) quinazolin-4 (3H) -one (145mg,0.34mmol) was dissolved in dichloromethane (2mL), added dropwise to the above formic acid solution, reacted at 0 ℃ for 2H, adjusted to pH 8-9 with sodium hydroxide solution, extracted with dichloromethane (15mL), and the organic phase evaporated to dryness to give the crude product.
Preparation of 6- (4-cyclopropyl-1H-imidazol-1-yl) -3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) quinazolin-4 (3H) -one
Crude N- (2-cyclopropyl-2-oxoethyl) -N- (3- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -4-oxo-3, 4-dihydroquinazolin-6-yl) carboxamide, ammonium acetate (104mg,1.35mmol), was added to glacial acetic acid (5mL), reacted at 110 ℃ for 20H, pH 7-8 was adjusted with sodium hydroxide solution, dichloromethane (15mL) was added for extraction, the organic phase was evaporated to dryness, and TLC plates (developing solvent methanol: dichloromethane ═ 1:12) gave the title compound (37mg, total yield in two steps: 24.8%).
The molecular formula is as follows: c24H22N8O molecular weight: 438.5 LC-MS (M/e): 439.2(M + H)+)
1H-NMR(CDCl3)δ:8.58(s,1H),8.47-8.45(d,1H),8.41(s,1H),8.35-8.34(d,1H),8.13-8.09(t,1H),7.97-7.95(d,1H),7.91-7.83(m,3H),7.16(s,1H),5.53-5.46(m,1H),1.98-1.90(m,1H),1.58-1.56(m,6H),0.95-0.89(m,2H),0.87-0.84(m,2H).
EXAMPLE 72 preparation of (6- ([1,2,4] triazolo [4,3-a ] pyridin-3-yl) pyridin-2-yl) -7- (4-cyclopropyl-1H-imidazol-1-yl) isoquinolin-1 (2H) -one (Compound 7)
Preparation of methyl 2- (2- (dimethylamino) ethenyl) -5-nitrobenzoate
Methyl 2-methyl-5-nitrobenzoate (7.0g,35.9mmol) was dissolved in 1-tert-butoxy-N, N, N ', N' -tetramethylmethanediamine (9.4g,53.9mmol) and heated to 115 ℃ for 2 hours. Solid is separated out and filtered, and filter cake is treated by petroleum ether: ethyl acetate (6:1,60mL) was slurry washed, filtered, and the filter cake was dried to give 8.1g of the desired product in 90.2% yield.
Preparation of 2,2- (2, 4-dimethoxybenzyl) -7-nitro-1 (2H) -isoquinolinone
Methyl 2- (2- (dimethylamino) vinyl) -5-nitrobenzoate (8.1g,32.4mmol), 2, 4-dimethoxybenzylamine (7.6g,45.4mmol) was dissolved in toluene (80mL), heated to 125 ℃ for 2.5 h to precipitate a solid, cooled to 25 ℃, filtered, and the filter cake was washed with petroleum ether: ethyl acetate (2:1, 100mL) was slurry washed, filtered, and the filter cake was dried to give 9.0g of the desired product in 81.6% yield.
Preparation of 3, 7-amino-2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one
2- (2, 4-Dimethoxybenzyl) -7-nitro-1 (2H) -isoquinolinone (8.4g,24.7mmol), zinc powder (8.1g,123.8mmol), ammonium chloride (7.9g,147.7mmol) were added to methanol (100mL) and water (100mL) in this order and reacted at 80 ℃ for 4 hours. Filtration was carried out, the filtrate was extracted with methylene chloride (300 mL. times.3) by adding water (100mL), the organic phases were combined, dried over anhydrous sodium sulfate, and filtered, and the filtrate was concentrated to obtain 7.4g of the objective product, yield: 96.6%.
Preparation of 4, 7- ((2-cyclopropyl-2-oxoethyl) amino) -2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one
7-amino-2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one (5.0g,16.1mmol), 2-bromo-1-cyclopropylethanone (3.1g,19.0mmol), DIEA (4.2g,32.6mmol) were added to dichloromethane (30mL), tetrahydrofuran (15mL), toluene (15mL) in that order and reacted at 80 ℃ for 5 hours. Concentration and purification of the residue by silica gel column (petroleum ether: ethyl acetate: 5:1-1:1) gave 3.6g of the objective product in 57.0% yield.
7.5 preparation of N- (2-cyclopropyl-2-oxoethyl) -N- (2- (2, 4-dimethoxybenzyl) -1-oxo-1, 2-dihydroisoquinolin-7-yl) carboxamide
Acetic anhydride (5.2g,50.9mmol) was added dropwise to formic acid (30mL) at 0 ℃ for 0.5 hour, and then a solution of 7- ((2-cyclopropyl-2-oxoethyl) amino) -2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one (5.0g,12.7mmol) in methylene chloride (30mL) was added dropwise to the reaction system and reacted at 0 ℃ for 16 hours. The pH was adjusted to 7 with NaOH (1M), extracted with dichloromethane (400mL methane), the organic phases were combined, dried over anhydrous sodium sulfate and concentrated to give crude 5.0 g.
Preparation of 7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one
N- (2-cyclopropyl-2-oxoethyl) -N- (2- (2, 4-dimethoxybenzyl) -1-oxo-1, 2-dihydroisoquinolin-7-yl) carboxamide (5.0g, crude product), ammonium acetate (7.5g,97.3mmol) were added to acetic acid (30mL), reacted at 105 ℃ for 16 hours, cooled to 0 ℃, adjusted to pH 7 with NaOH (2M), extracted with dichloromethane (150mL methane), the organic phases combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude product 5.1 g.
7.7 preparation of 7- (4-cyclopropyl-1H-imidazol-1-yl) isoquinolin-1 (2H) -one
7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (2, 4-dimethoxybenzyl) isoquinolin-1 (2H) -one (5.1g, crude) was dissolved in trifluoroacetic acid (30mL) and reacted at 90 ℃ for 3 hours. Concentration, slurrying of the residue with ethyl acetate (50mL), filtration, and drying of the cake to obtain 2.2g of the objective product, in a three-step yield of 68.9%.
Preparation of 2- (6- ([1,2,4] triazolo [4,3-a ] pyridin-3-yl) pyridin-2-yl) -7- (4-cyclopropyl-1H-imidazol-1-yl) isoquinolin-1 (2H) -one
7- (4-cyclopropyl-1H-imidazol-1-yl) isoquinolin-1 (2H) -one (0.21g,0.84mmol), 3- (6-chloropyridin-2-yl) - [1,2, 4%]Triazolo [4,3-a]Pyridine (196mg,0.85mmol), cesium carbonate (0.55g,1.69mmol), Pd2(dba)3(46mg,0.05mmol) and Xantphos (29mg,0.05mmol) were added sequentially to dioxane (50mL) and reacted at 120 ℃ for 16 hours. The concentrate was purified by reverse phase C18 column (water/methanol 10% to 35%) to obtain the objective product (50mg, yield: 13.4%).
Molecular formula C26H19N7O molecular weight 445.49 LC-MS (M/e):446.2(M + H)+)
1H-NMR(400MHz,DMSO-d6)δ:9.47(d,J=5.6Hz,1H),9.39(s,1H),8.55(s,1H),8.45(d,J=6.8Hz,1H),8.20-9.30(m,1H),7.93-8.13(m,6H),7.52(s,1H),7.16(s,1H),6.95(d,J=6.0Hz,1H),1.98(s,1H),0.99(m,2H),0.84(s,2H).
Example 87 preparation of- (4-cyclopropyl-1H-imidazol-1-yl) -4, 4-difluoro-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one (Compound 8)
Preparation of 1, 7- (4-cyclopropyl-1H-imidazol-1-yl) -4, 4-difluoro-3-hydroxy-3, 4-dihydroisoquinolin-1 (2H) -one
The compound 7- (4-cyclopropyl-1H-imidazol-1-yl) -4-fluoroisoquinolin-1 (2H) -one (269mg,1mmol) and 1-chloromethyl-4-fluoro-1, 4-diazobicyclo 2.2.2 octane bis (tetrafluoroborate) salt (709mg,2mmol) were dissolved in acetonitrile (10mL), and water (1mL) was added to react at 60 ℃ for 2 hours. After the reaction was completed, the reaction solution was concentrated, and the residue was prepared under medium pressure (0-50% methanol) to obtain the objective compound (122mg, yield 40.0%).
Preparation of 2, 7- (4-cyclopropyl-1H-imidazol-1-yl) -4, 4-difluoro-3, 4-dihydroisoquinolin-1 (2H) -one
7- (4-cyclopropyl-1H-imidazol-1-yl) -4, 4-difluoro-3-hydroxy-3, 4-dihydroisoquinolin-1 (2H) -one (122mg, 0.4mmol), triethylsilane (1mL), and trifluoroacetic acid (1mL) were added to a microwave tube, and reacted at 70 ℃ for 10 hours with a microwave. After the reaction was completed, the residue was purified by silica gel column chromatography (methanol: dichloromethane ═ 1:20) to obtain the objective compound (24mg, yield 20.8%). Preparation of 7- (4-cyclopropyl-1H-imidazol-1-yl) -4, 4-difluoro-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one
The compound 7- (4-cyclopropyl-1H-imidazol-1-yl) -4, 4-difluoro-3, 4-dihydroisoquinolin-1 (2H) -one (24mg, 0.083mmol), 2-bromo-6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridine (22mg, 0.083mmol), 2-dicyclohexylphosphonium-2, 4, 6-triisopropylbiphenyl (4mg, 20%), palladium acetate (2mg, 10%) and cesium carbonate (54mg, 0.166mmol) were dissolved in 1, 4-dioxane (5mL) and reacted at 110 ℃ for 2 hours under nitrogen atmosphere. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol ═ 20:1) to give the objective compound (8mg, yield 20.3%).
The molecular formula is as follows: c25H23F2N7O molecular weight: 475.5 LC-MS (M/e):238.5(M + H/2),475.9(M + H)
1H-NMR(400MHz,CDCl3)δ:8.40(s,1H),8.28(s,1H),8.20(d,J=7.6Hz),8.12(d,J=8.0Hz,1H),7.98(t,J=8.0Hz,1H),7.85-7.93(m,2H),7.72-7.78(m,1H),7.15(s,1H),5.40-5.55(m,1H),4.65(t J=12.0Hz,2H),1.90-1.98(m,1H),1.58-1.63(m,6H),0.85-0.98(m,4H)。
EXAMPLE 97- (4-cyclopropyl-1H-imidazol-1-yl) -5-fluoro-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one preparation (Compound 9)
9.17-bromo-5-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one preparation
6-bromo-4-fluoro-2, 3-dihydro-1H-inden-1-one (5g,21.8mmol) was dissolved in a mixed solution of dichloromethane (60mL) and methanesulfonic acid (30mL), and sodium azide (2.1g,32.3mmol) was added at 0 ℃ to react at 20 ℃ for 2 hours. After the reaction was completed, water was slowly added at 0 ℃ to quench the reaction, then water (100mL) and dichloromethane (50mL) were added, the layers were separated, the aqueous layer was extracted with dichloromethane (50mL × 2), the organic layers were combined, concentrated, and the residue was purified by column chromatography (petroleum ether: ethyl acetate ═ 2:1) to give the product (2.4g, yield 45.3%).
9.22- ((benzyloxy) methyl) -7-bromo-5-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one preparation
7-bromo-5-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one (2g,8.2mmol) was dissolved in DMF (20mL), sodium hydride (656mg,16.4mmol) was added, and after stirring for one hour ((chloromethoxy) methyl) benzene (1.9g,12.2mmol) was added, and the reaction was carried out at 20 ℃ for 4 hours. After the reaction was completed, 100mL of water and 50mL of ethyl acetate were added, liquid separation was performed, the aqueous phase was extracted with ethyl acetate (50mL × 2), the organic phases were combined, concentrated, and the residue was subjected to column chromatography (petroleum ether: ethyl acetate ═ 10:1) to give the product (2.3g, yield 76.7%).
9.32- ((benzyloxy) methyl) -7- (4-cyclopropyl-1H-imidazol-1-yl) -5-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one preparation
Dissolving 2- ((benzyloxy) methyl) -7-bromo-5-fluoro-3, 4-dihydroisoquinoline-1 (2H) -one (1.2g,3.3mmol) and cyclopropylimidazole (356mg,3.3mmol) in DMF (6mL), adding cuprous iodide (125mg,0.66mmol), phenanthroline (118mg,0.66mmol) and potassium carbonate (910mg,6.6mmol), and carrying out microwave reaction at 120 ℃ for 7 hours under the protection of nitrogen. After filtration, water (50mL) and ethyl acetate (50mL) were added to the filtrate, followed by liquid separation, the aqueous phase was extracted with ethyl acetate (50mL × 2), the organic phases were combined, concentrated, and the residue was subjected to column chromatography (petroleum ether: ethyl acetate ═ 2:1) to give the product (680mg, yield 52.6%).
9.47- (4-cyclopropyl-1H-imidazol-1-yl) -5-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one preparation
2- ((benzyloxy) methyl) -7- (4-cyclopropyl-1H-imidazol-1-yl) -5-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one (500mg,1.3mmol) was dissolved in TFA (20mL) and reacted at 80 ℃ for 36 hours. Concentration, addition of dichloro (50mL) methane and sodium bicarbonate solution (50mL) to the residue, liquid separation with stirring for half an hour, extraction of the aqueous phase with dichloromethane (20mL × 2), combination of the organic phases, concentration, and column chromatography of the residue (ethyl acetate: methanol ═ 20:1) gave the product (180mg, 51.1% yield).
Preparation of 57- (4-cyclopropyl-1H-imidazol-1-yl) -5-fluoro-2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one
The reaction mixture was washed with 7- (4-cyclopropyl-1H-imidazol-1-yl) -5-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one (100mg,0.37mmol), 2-bromo-6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridine (100mg,0.37mmol), cesium carbonate (241mg,0.74mmol), Pd (OAc)2(8mg,0.037mmol) and Xphos (35mg,0.073mmol) were added to 1, 4-dioxane (10mL) and reacted at 110 ℃ under nitrogen for 16h, after completion of the reaction, filtration was carried out, the filtrate was concentrated and the residue was isolated by TLC to give the product (85mg, 50.3% yield).
The molecular formula is as follows: c25H24FN7O molecular weight: 457.5 LC-MS (M/e): 458.2(M + H)+)
1HNMR(400MHz,MeOD)δ:8.86(s,1H),8.11(s,1H),8.07-8.08(m,1H),8.03-8.05(m,2H),7.96-7.99(m,1H),7.67-7.70(m,1H),7.40(s,1H),5.48-5.52(m,1H),4.35(t,J=6.4Hz,2H),3.23(t,J=6.4Hz,2H),1.80-1.95(m,1H),1.59(d,J=6.8Hz,1H),0.86-0.90(m,2H),0.74-0.78(m,2H)
Example 107- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one preparation (Compound 10)
10.1 preparation of 2- (3- (6-bromopyridin-2-yl) -4H-1,2, 4-triazol-4-yl) propan-1-ol
N' - (6-Bromopyridinoyl) -N, N-dimethylformylhydrazone amide (2.7g,10.0mmol) and acetic acid (10mL) were added to acetonitrile (40mL), DL-alaninol (3.76g,50.0mmol) was added, and the mixture was heated to 95 ℃ for reaction at room temperature for 6 hours. The system was adjusted to pH 8 with sodium hydroxide solution, EA (100mL) and saturated sodium chloride solution (80mL) were added, the organic phase was dried over anhydrous sodium sulfate, and the solvent was dried to give the product (1.4g, 49.5% yield).
Preparation of 2, 7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4-isopropyl-4H-1, 2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one
Mixing 7- (4-cyclopropyl-1H-imidazol-1-yl) -3, 4-dihydroisoquinolin-1 (2H) -one (200mg,0.79mmol), 2- (3- (6-bromopyridin-2-yl) -4H-1,2, 4-triazol-4-yl) propan-1-ol (223.7mg,0.79mmol), cesium carbonate (514.8mg,1.58mmol), Pd (OAc)2(17.7mg,0.079mmol) and X-phos (37.7mg,0.079mmol) were added to 1, 4-dioxane (20mL), the reaction was stirred at 102 ℃ for 2 hours under nitrogen, the system was filtered with suction, and the filtrate was filtered through C18Column chromatography (water: acetonitrile ═ 6:4) afforded the product (180mg, 50.1% yield).
The molecular formula is as follows: c25H25N7O2Molecular weight: 455.5 LC-MS (M/e): 456.3(M + H)+)
1H-NMR(400MHz,DMSO)δ:8.88(s,1H),8.13-8.05(m,2H),8.05-7.96(m,1H),7.96-7.91(m,2H),7.78-7.71(m,1H),7.55-7.45(m,2H),5.36-5.28(m,1H),5.04-4.98(m,1H),4.23-4.18(m,2H),3.72-3.62(m,2H),1.90-1.78(m,1H),1.47-1.39(m,3H),0.82-0.75(m,2H),0.75-0.68(m,2H)。
Example 117- (4-cyclopropyl-1H-imidazol-1-yl) -6-fluoro-2- (6- (4- (1-hydroxypropan-2 yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one preparation (Compound 14)
11.1 preparation of methyl (3-fluorophenethyl) carbamate
2- (3-fluorophenyl) ethan-1-amine (10.0g,71.8mmol) and triethylamine (13.0mL,93.3mmol) were dissolved in dichloromethane (140mL), methyl chloroformate (6.1mL,79mmol) was added at 0 ℃, reacted at 0 ℃ for 1h, concentrated, and purified on silica gel column (petroleum ether: ethyl acetate ═ 2:1) to give the product (10.0g, yield: 71%).
Preparation of 2, 6-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one
To methyl (3-fluorophenethyl) carbamate (9.0g,46mmol) was slowly added trifluoromethanesulfonic acid (45mL,510mmol) at 0 deg.C, reacted at 70 deg.C for 25 hours, the reaction solution was poured into ice water (300mL), extracted with dichloromethane (100 mL. times.3), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated to give the crude product which was directly subjected to the next reaction.
Preparation of 3, 6-fluoro-7-nitro-3, 4-dihydroisoquinolin-1 (2H) -one
Slowly adding potassium nitrate (6.6g,65mmol) into a concentrated sulfuric acid solution (65mL) of 6-fluoro-3, 4-dihydroisoquinoline-1 (2H) -ketone (8.26g, crude product) at 0 ℃, reacting for 20 minutes at 0 ℃, pouring the reaction solution into ice water (200mL), filtering, washing (100mL) of a filter cake, pulping (20mL) with methanol, and performing suction filtration and drying to obtain the crude product to directly perform the next reaction.
Preparation of 4, 7-amino-6-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one
6-fluoro-7-nitro-3, 4-dihydroisoquinolin-1 (2H) -one crude product (5.0g,23.8mmol) and iron powder (6.7g,119mmol) were added to acetic acid (150mL) and tetrahydrofuran (70mL) and reacted at 70 ℃ for 4 hours. The filtrate was filtered and concentrated on silica gel column to give the product (6.5 g).
Preparation of 5, 7- ((2-cyclopropyl-2-oxoethyl) amino) -6-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one
7-amino-6-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one (5.8g,32.2mmol), 2-bromo-1-cyclopropylethanone (3.7g,38mmol) and DIEA (26.4mL,155.5mmol) were added sequentially to tetrahydrofuran (55mL) and toluene (250mL) and reacted at 100 ℃ for 16 hours. Concentration and silica gel column purification (petroleum ether: ethyl acetate: 3:1) gave the product (5.6g, yield: 66%).
11.6 preparation of N- (2-cyclopropyl-2-oxoethyl) -N- (6-fluoro-1-oxo-1, 2,3, 4-tetrahydroisoquinolin-7-yl) carboxamide
Acetic anhydride (778mg,7.6mmol) was dropped into formic acid (10mL) at 0 ℃ for 0.5 hour, and then a solution of 7- ((2-cyclopropyl-2-oxoethyl) amino) -6-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one (500mg,1.9mmol) in methylene chloride (10mL) was dropped into the reaction system to react at 0 ℃ for 16 hours. The pH was adjusted to 7 with NaOH (1M), dichloromethane (400mL) was extracted, the organic phases were combined, dried over anhydrous sodium sulfate and concentrated to give the crude product which was directly subjected to the next reaction.
11.7 preparation of 7- (4-cyclopropyl-1H-imidazol-1-yl) -6-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one
N- (2-cyclopropyl-2-oxoethyl) -N- (6-fluoro-1-oxo-1, 2,3, 4-tetrahydroisoquinolin-7-yl) carboxamide (500mg, crude), ammonium acetate (586mg,7.6mmol) were added to acetic acid (10mL), reacted at 110 ℃ for 16 hours, cooled to 0 ℃, adjusted pH 9 with NaOH (2M), extracted with ethyl acetate (500mL × 2), the organic phases combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to give crude (247mg, 48% yield over two steps).
Preparation of 7- (4-cyclopropyl-1H-imidazol-1-yl) -6-fluoro-2- (6- (4- (1-hydroxypropan-2 yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one
Mixing 7- (4-cyclopropyl-1H-imidazol-1-yl) -6-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one (100mg,0.37mmol), 2- (3- (6-bromopyridin-2-yl) -4H-1,2, 4-triazol-4-yl) propan-1-ol (125mg,0.44mmol), cesium carbonate (240mg,0.74mmol), Pd (OAc)2(9mg,0.04mmol) and X-phos (38mg,0.08mmol) were added to 1, 4-dioxane (20mL) and reacted at 110 ℃ under nitrogen for 16h, after completion of the reaction, filtration, concentration of the filtrate and TLC separation of the residue to give the crude product which was prepared in reverse phase (32mg, 18.3% yield).
The molecular formula is as follows: c25H24FN7O2Molecular weight: 473.5 LC-MS (M/e): 474.2(M + H)+)
1H-NMR(400MHz,MeOD)δ:8.82(s,1H),8.19(d,J=7.6Hz,1H),7.88-8.02(m,4H),7.41(d,J=10.8Hz,1H),7.21(s,1H),5.45-5.51(m,1H),4.32(t,J=6.4Hz,2H),3.85(d,J=5.2Hz,1H),3.23-3.26(m,2H),1.87-1.93(m,1H),1.58(d,J=6.8Hz,1H),0.86-0.91(m,2H),0.75-0.68(m,2H)。
EXAMPLE 12 preparation of (R) -7- (4-cyclopropyl-1H-imidazol-1-yl) -6-fluoro-2- (6- (4- (1-hydroxypropan-2-yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one (Compound 15)
Preparation of (R) -7- (4-cyclopropyl-1H-imidazol-1-yl) -6-fluoro-2- (6- (4- (1-hydroxypropan-2-yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one
The reaction mixture was washed with 7- (4-cyclopropyl-1H-imidazol-1-yl) -6-fluoro-3, 4-dihydroisoquinolin-1 (2H) -one (100mg,0.37mmol), (R) -2- (3- (6-bromopyridin-2-yl) -4H-1,2, 4-triazol-4-yl) propan-1-ol (115mg,0.41mmol), cesium carbonate (240mg,0.74mmol), Pd (OAc)2(8mg,0.04mmol) and Xphos (35mg,0.07mmol) were added to 1, 4-dioxane (10mL) and reacted at 110 ℃ under nitrogen for 16 hours, after completion of the reaction, filtration was carried out, the filtrate was concentrated, and the residue was purified by TLC (dichloromethane: methanol ═ 10:1) to give a compound (42mg, 24% yield).
Molecular formula:C25H24FN7O2Molecular weight: 473.5 LC-MS (M/e): 474.2(M + H)+)
1HNMR(400MHz,MeOD)δ:8.83(s,1H),8.20(d,J=7.6Hz,1H),7.96-7.98(m,3H),7.89(s,1H),7.42(d,J=10.8Hz,1H),7.22(s,1H),5.45-5.51(m,1H),4.33(t,J=6.4Hz,2H),3.85(d,J=5.2Hz,1H),3.23-3.26(m,2H),1.87-1.93(m,1H),1.58(d,J=6.8Hz,1H),0.86-0.91(m,2H),0.75-0.78(m,2H)。
EXAMPLE 13 preparation of (R) -7- (4-cyclopropyl-1H-imidazol-1-yl) -4, 4-difluoro-2- (6- (4- (1-hydroxypropan-2-yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) -3, 4-dihydroisoquinolin-1 (2H) -one (Compound 20)
13.1 Synthesis of (R) -7- (4-cyclopropyl-1H-imidazol-1-yl) -4, 4-difluoro-2- (6- (4- (1-hydroxypropan-2-yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) -34-dihydroisoquinolin-1 (2H) -one
The compound 7- (4-cyclopropyl-1H-imidazol-1-yl) -4, 4-difluoro-3, 4-dihydroisoquinolin-1 (2H) -one (46mg, 0.159mmol), (R) -2- (3- (6-bromopyridin-2-yl) -4H-1,2, 4-triazol-4-yl) propan-1-ol (45mg, 0.159mmol), 2-dicyclohexylphosphonium-2, 4, 6-triisopropylbiphenyl (10mg, 20%), palladium acetate (5mg, 10%) and cesium carbonate (104mg, 0.318mmol) were dissolved in 1, 4-dioxane (10mL) and reacted at 110 ℃ for 18 hours under nitrogen protection. The reaction solution was concentrated, and the residue was purified by silica gel column chromatography (dichloromethane: methanol ═ 15:1) to give the objective compound (8mg, yield 10.2%).
The molecular formula is as follows: c25H23F2N7O2Molecular weight: 491.5 LC-MS (M/e):246.7(M + H/2),492.2(M + H)
1H-NMR(400MHz,MeOD)δ:8.85(s,1H),8.36(s,1H),8.21(d,J=1.2Hz,1H),8.06-8.15(m,2H),8.00-8.05(m,2H),7.94-7.98(m,1H),7.48(s,1H),5.45-5.55(m,1H),4.78(t,J=12.0Hz,2H),3.87(d,J=4.8Hz,2H),1.89-1.96(m,1H),1.60(d,J=6.8Hz,3H),0.75-0.95(m,4H)。
Preparation example 147- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4- (1-hydroxypropan-2-yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one preparation (Compound 21)
Preparation of 1, 7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4- (1-hydroxypropan-2-yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one
7- (4-cyclopropyl-1H-imidazol-1-yl) isoquinolin-1 (2H) -one (0.2g,0.79mmol), 2- (3- (6-bromopyridin-2-yl) -4H-1,2, 4-triazol-4-yl) propan-1-ol (225mg,0.79mmol), potassium carbonate (0.21g,1.6mmol), cuprous iodide (75mg,0.39mmol) and 8-hydroxyquinoline (57mg,0.39mmol) were added sequentially to DMSO (8mL), N2The reaction is carried out for 16 hours at the protection temperature of 100 ℃. The reaction was poured into water (50mL), filtered and the filter cake was TLC separated (DCM: MeOH ═ 10:1) to give the product (80mg, yield: 22.3%).
Molecular formula C25H23N7O2Molecular weight 453.51 LC-MS (M/e):454.2(M + H)+)
1H-NMR(400MHz,DMSO)δ:8.82(s,1H),8.35(d,J=2.0Hz,1H),8.25(s,1H),8.16-8.20(m,2H),8.05-8.08(m,1H),7.97-7.99(dd,J=2.0Hz,J=7.2Hz,1H),7.89(d,J=8.8Hz,1H),7.82(d,J=7.2Hz,1H),7.64(s,1H),6.86(d,J=7.6Hz,1H),5.26(q,J=6.8Hz,1H),5.00(t,J=5.6Hz,1H),3.67(t,J=5.6Hz,2H),1.83-1.87(m,1H),1.43(d,J=6.8Hz,3H),0.78-0.83(m,2H),0.69-0.73(m,2H)。
EXAMPLE 15 preparation of (R) -7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4- (1-hydroxypropan-2-yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one (Compound 22)
15.1 preparation of (R) -7- (4-cyclopropyl-1H-imidazol-1-yl) -2- (6- (4- (1-hydroxypropan-2-yl) -4H-1,2, 4-triazol-3-yl) pyridin-2-yl) isoquinolin-1 (2H) -one
7- (4-cyclopropyl-1H-imidazol-1-yl) isoquinolin-1 (2H) -one (0.18g,0.72 mmo)l), (R) -2- (3- (6-bromopyridin-2-yl) -4H-1,2, 4-triazol-4-yl) propan-1-ol (202mg,0.72mmol), potassium carbonate (0.3g,2.1mmol), cuprous iodide (70mg,0.37mmol) and 8-hydroxyquinoline (54mg,0.37mmol) were added sequentially to DMSO (8mL), N2The reaction is carried out for 16 hours at the protection temperature of 100 ℃. The reaction was poured into water (50mL), filtered and the filter cake was TLC separated (DCM: MeOH ═ 8:1) to give the product (50mg, yield: 15.3%).
Molecular formula C25H23N7O2Molecular weight 453.51 LC-MS (M/e):454.2(M + H)+)
1H-NMR(400MHz,DMSO)δ:8.71(s,1H),8.35(d,J=2.0Hz,1H),8.24(s,1H),8.16-8.22(m,2H),8.05-8.08(m,1H),7.96-7.99(dd,J=1.6Hz,J=5.1Hz,1H),7.88(d,J=8.8Hz,1H),7.82(d,J=7.2Hz,1H),7.64(s,1H),6.86(d,J=7.6Hz,1H),5.26(q,J=6.0Hz,1H),5.00(t,J=5.2Hz,1H),3.67(t,J=5.6Hz,2H),1.83-1.87(m,1H),1.43(d,J=6.4Hz,3H),0.78-0.83(m,2H),0.69-0.73(m,2H).
The beneficial effects of the compounds of the present invention are further illustrated below by in vitro enzymology and cytostatic activity experiments and pharmacokinetic experiments, but this should not be understood as the only beneficial effects of the compounds of the present invention.
Biological Experimental example
Experimental example 1: in vitro enzymatic Activity of Compounds of the invention
And (3) testing the sample: the structural formula of the compound synthesized in the embodiment of the invention is shown in table 1.
Experimental materials:
preparing a reagent:
kinase detection buffer (kinase detection buffer)
a. Unfreezing the kinase detection buffer to room temperature, and observing whether a precipitate exists or not;
b. if a precipitate is present, the kinase detection buffer is incubated at 37 ℃ and vortexed for 15min to dissolve the precipitate, or the precipitate is removed from the kinase detection buffer.
Kinase detection reagent
a. Equilibrating kinase detection buffer and kinase detection substrate to room temperature;
b. transferring all volume kinase detection buffers to a kinase detection subsystem to form a kinase detection reagent;
c. vortex, mix well to form a homogeneous solution, and the kinase detection substrate is added to the solution for at least 1 min.
The experimental method comprises the following steps:
1. dilution of Compounds
a. Staurosporine was diluted to 1mM, the compound of the invention to 1mM, using DMSO as a stock solution.
b. Staurosporine and the compound stock solution of the invention were diluted 1000-fold to 1 μ M.
c. Staursporine was diluted 3-fold in gradient to 11 concentrations with a maximum concentration of 1 μ M and the compound of the invention was diluted 3-fold in gradient to 11 concentrations with a maximum concentration of 1 μ M using the TECAN EVO2000 system.
d. Echo550 was used to transfer 20nLStaurosporine, a compound of the present invention, respectively, to 384 well plates.
2. Experiment of enzyme reaction
1) A1.3 Xenzyme reaction system comprising a kinase, a substrate and factors required for the reaction was prepared as shown in Table 2.
2) To the reaction well, 15. mu.L of 1.3 Xenzyme reaction system was added and incubated at room temperature for 30 minutes.
TABLE 2.1.3 Xenzyme reaction System
3) The enzyme reaction was initiated by adding 5. mu.L of 4 × ATP solution (see Table 3) to each well.
TABLE 3.4 XATP solution
4) After the reaction system is placed at 25 ℃ for 90 minutes, add20 μ L ADP-GloTMReagent was incubated for 40 minutes.
5) Incubation for 35 min with 40. mu.L of Kinase Detection Regent, EnSpireTMThe fluorescence was read by a microplate reader.
3. Data analysis
The Remaining enzyme Activity (% Remaining Activity) was calculated using the following formula:
Remaining Activity(%)=100%×(Lumcpd-LumLC)/(LumHC-LumLC)
wherein, LumHCRepresents: the intensity of a luminescent signal of High control (the reaction system contains DMSO at the same concentration as the compound assay);
LumLCrepresents: luminescence signal intensity of Low control (Staursporine 1. mu.M);
Lumcpdrepresents: indicating the intensity of the luminescent signal of the test compound;
curve fitting is carried out by adopting XLFIT software to obtain IC50。
The experimental results are as follows:
TABLE 4 inhibitory Activity of the Compounds of the invention on ASK1
From the experimental results, the compound prepared by the invention can effectively inhibit the phosphorylation of the amino acid of ASK1 and inhibit the activation of ASK1, and is an effective ASK1 inhibitor.
In addition, the prior art has reported that ASK1 inhibitors have preventive and/or therapeutic effects on ASK 1-mediated diseases and related diseases; namely, the compound shown in the general formula (I), (II), (III), (IV) or (V) can prevent and/or treat the ASK1 mediated diseases and related diseases.
Experimental example 2 in vitro cytological Activity of Compounds of the invention
And (3) testing the sample: the chemical name and the structural formula of the compound synthesized in the embodiment of the invention are shown in table 1.
Experimental materials:
wherein: cell culture medium composition: DMEM + 10% FBS +1 XPS
The experimental method comprises the following steps:
1. transfection
1) 25. mu.L of the transfection reagent Lipofectamine2000 was mixed with 0.7mL of Opti-MEM medium, and 0.7mL of Opti-MEM medium was used to dilute the plasmid DNA (pGL4.44(luc2P-AP1-RE-Hygro, AP1 for short) and pcDNA3.1/pcDNA3.1-hASK1), followed by incubation at room temperature for 5 min.
2) After 5min incubation, the plasmid DNA mixture was added to the transfection reagent Lipo2000 mixture, mixed well and incubated for 20min at room temperature.
3) Adding the mixed solution into a culture dish containing HEK-293T cells for transfection, and placing the culture dish at 37 ℃ and 5% CO2Incubate in incubator for 16 h.
2. Test Compound dilution and cell plating
1) Diluting the test compound to 10mM stock solution with DMSO, and diluting the stock solution to 10 concentrations with a 3-fold gradient using a TECAN EVO2000 system;
2) transferring 30nL of each concentration of test compound into 384-well cell culture plates using Echo 550;
3) the transfected cells were collected, counted, and according to the result of cell counting, the cells were diluted with a medium to a desired density, and then 30. mu.L of a cell suspension (about 10000 cells) was added to a 384-well cell culture plate containing the compound to be tested, and the cell culture plate was placed at 37 ℃ with 5% CO2Incubate in incubator for 24 h.
3. Detection of
1) Taking the 384-well cell culture plate of the step 2.3 out of the incubator, and balancing for 15min at room temperature;
2) before the experiment, unfreezeLuciferase reagent, and equilibrating to room temperature;
3) adding 30 μ LAnd (3) incubating the Luciferase reagent to a 384-well plate at room temperature for 10min, and reading the plate by using a microplate reader.
4. Data analysis
1) The Remaining Activity (% Remaining Activity) was calculated using the following formula:
Remaining Activity(%)=100%×(Lumsample-LumNC)/(LumPC-LumNC)
wherein, LumPC: average values of the luminescence signal values of wells co-transfected with ASK1 and AP 1;
LumNC: average of values of the luminescence signal from wells transfected with AP 1;
Lumsample: means for representing the average of the luminescence signal values of the test compound;
2) curve fitting is carried out by adopting XLFIT software to obtain IC50The value is obtained.
The experimental results are as follows:
TABLE 5 in vitro cytological Activity of Compounds of the invention
As can be seen from the above experimental results, in vitro cell experiments, the compound of the present invention can effectively block the phosphorylation of ASK1 in cells and block the activation of downstream pathways, and thus, the compound of the present invention can be effectively used for treating related diseases mediated by ASK 1.
Experimental example 3: c57BL/6 mouse in vivo pharmacokinetic experiments with Compounds of the invention
And (3) testing the sample: the chemical name and the preparation method of part of the compound of the invention, self-made, are shown in the preparation examples of each compound.
The test animals were: male mice (C57BL/6), 9/route of administration/compound, weight 22-26 g/mouse.
Preparing a test solution:
dissolution scheme:
compound 1 IV administration: 2% DMSO + 10% PEG400+ 88% (28% HP-beta-CD)
Compound 1 PO administration: 0.1% SDS + 0.5% MC
Compound 2 IV administration: 2% DMSO + 10% PEG400+ 88% (28% HP-beta-CD)
Compound 2 PO administration: 2% HPC + 0.1% Tween80
Compound 3 IV administration: 3% DMSO + 5% PEG400+ 92% (28% HP-beta-CD)
Compound 3 PO administration: 2% HPC + 0.1% Tween80
Preparation of a blank solvent 1:
the preparation method of the 28 percent HP-beta-CD solution comprises the following steps: HP- β -CD (hydroxypropyl betacyclodextrin) (28g) was weighed and sterile water for injection (72mL) was added to give a 28% solution of HP- β -CD.
Preparation of a blank solvent 2:
preparation of 2% HPC + 0.1% tween 80: HPC (hydroxypropyl cellulose) (30g) was weighed, slowly added to stirred purified water (1470mL), and Tween80 (1.5mL) was added, stirred until clear.
Preparation of a blank solvent 3:
preparation of 0.5% MC: weighing 5g of MC (methyl cellulose), slowly adding 500mL of stirred purified water, stirring until the mixture is clear and transparent, then adding purified water to a constant volume of 1000mL, and stirring uniformly.
The preparation method comprises the following steps:
compound 1:
weighing the compound 1(1.48mg), adding DMSO (dimethyl sulfoxide) (48.4 mu L), carrying out ultrasonic dissolution, adding PEG400 (polyethylene glycol 400) (242.2 mu L), carrying out vortex mixing, finally adding a blank solvent 1(2.131mL), carrying out vortex mixing, preparing a colorless transparent solution with the concentration of 0.6mg/mL, and taking the solution as compound 1C57BL/6 mouse IV administration liquid medicine 1;
compound 1(1.51mg) and SDS (sodium dodecyl sulfate) (4.9mg) were weighed, added to blank vehicle 3(4.943mL), ground, vortexed and mixed to prepare a homogeneous suspension solution with a concentration of 0.3mg/mL, which was used as PO administration solution 2 of compound 1C57BL/6 mouse.
Compound 2:
weighing a compound 2(1.50mg), adding DMSO (dimethyl sulfoxide) (47.0 mu L), carrying out vortex and ultrasonic dissolution, adding PEG400 (polyethylene glycol 400) (233 mu L), carrying out vortex mixing, finally adding a blank solvent 1(2.05mL), carrying out vortex mixing, placing in a constant-temperature water bath kettle at 50 ℃ for heat preservation for 20min, carrying out vortex mixing, preparing into a uniform solution with the concentration of 0.6mg/mL, and taking the solution as a compound 2C57BL/6 mouse IV administration liquid medicine 1;
compound 2(1.51mg) was weighed, added to blank vehicle 2(4.691mL), ground, suspended uniformly, and prepared into a uniform suspension solution with a concentration of 0.3mg/mL, which was used as PO administration solution 2 of compound 2C57BL/6 mouse.
Compound 3:
weighing the compound 3(1.57mg), adding DMSO (dimethyl sulfoxide) (72.6 mu L), carrying out vortex and ultrasonic dissolution, then adding PEG400 (polyethylene glycol 400) (121 mu L), carrying out vortex mixing, finally adding a blank solvent 1(2.230mL), carrying out vortex mixing, preparing into a uniform solution with the concentration of 0.6mg/mL, and taking the solution as compound 3C57BL/6 mouse IV administration liquid medicine 1;
compound 3(1.50mg) was weighed, added to blank vehicle 2(4.620mL), ground, suspended uniformly, and prepared into a uniform suspension solution with a concentration of 0.3mg/mL, which was used as PO administration solution 2 for compound 3C57BL/6 mice.
Experimental methods
Administration:
the test liquid medicine is administered according to the following method:
blood collection:
collecting time points: 0.083, 0.25, 0.5, 1,2,4, 6, 8, 24h after administration
Approximately 100. mu.L of blood was collected from the canthus at each time point and placed in the eye containing EDTA-K2In the anticoagulant tube of the anticoagulant agent,centrifuging the blood sample at 4 deg.C for 6min at 8000 rpm to obtain plasma sample, and freezing the plasma in-80 deg.C refrigerator.
Plasma sample analysis
Plasma samples of control and compound were analyzed by protein precipitation: taking 20 mu L of plasma, adding 200 mu L of internal standard (acetonitrile solution containing 50ng/mL of tolbutamide), vortexing for 10min, then centrifuging for 20min at 4000 rpm, taking 100 mu L of supernatant, adding 100 mu L of water, vortexing and uniformly mixing for 3min, and then carrying out LC-MS/MS analysis.
The experimental results are as follows:
table 6: c57BL/6 mouse PK evaluation results (IV)
Table 7: c57BL/6 mouse PK evaluation results (PO)
AUCinfArea 0 → ∞ under curve when drug is represented
CL stands for clearance
VssRepresenting steady state apparent distribution volume
TmaxRepresenting the time to peak of blood concentration
CmaxRepresenting peak plasma concentration
T1/2Represents the half-life
F% represents absolute bioavailability
As shown in the experimental results in tables 6 and 7, the compound of the present invention has high exposure and high bioavailability, shows good pharmacokinetic properties, has good clinical application prospects, and is convenient for preparation of various clinical dosage forms.
Experimental example 4 in vivo pharmacokinetic experiment of beagle dog with the Compound of the present invention
And (3) testing the sample: the chemical name and the preparation method of the compound 2 are shown in the preparation examples of the compound.
The test animals were: male beagle dogs, control: 3 per administration route, body weight 8-11kg per body; a compound: 3/administration route, body weight 7-11 kg/body.
Preparing a test solution:
dissolution scheme:
compound IV administration: 5% DMSO + 20% PEG400+ 75% (28% HP-beta-CD)
Compound PO administration: 2% HPC + 0.1% Tween80
Preparation of a blank solvent 1:
the preparation method of the 28 percent HP-beta-CD solution comprises the following steps: HP- β -CD (hydroxypropyl betacyclodextrin) (28g) was weighed and sterile water for injection (72mL) was added to give a 28% solution of HP- β -CD.
Preparation of a blank solvent 2:
preparation of 2% HPC + 0.1% tween 80: HPC (hydroxypropyl cellulose) (30g) was weighed, slowly added to stirred purified water (1470mL), and Tween80 (1.5mL) was added, stirred until clear.
The preparation method comprises the following steps:
compound 2:
weighing a compound 2(40.49mg), adding DMSO (dimethyl sulfoxide) (1.99mL), carrying out vortex dissolution, adding PEG400 (polyethylene glycol 400) (7.96mL), carrying out vortex mixing, adding a blank solvent 1(29.85mL), carrying out vortex mixing, and preparing a colorless transparent solution with the concentration of 1mg/mL, wherein the solution is used as a compound beagle IV administration liquid medicine 1;
② weighing the compound 2(80.37mg), adding blank solvent 2(197.7mL), grinding, suspending evenly, preparing even suspension with concentration of 0.4mg/mL, and taking the solution as compound 2 beagle PO administration liquid medicine 2.
Experimental methods
Administration:
the test liquid medicine is administered according to the following method:
blood collection:
collecting time points:
compound IV administration group: 0.083, 0.25, 0.5, 1,2,4, 6, 8, 24 hours post-administration;
compound PO dosing group: 0.167, 0.5, 1,2,4, 6, 8, 24h after administration;
approximately 400 μ L of blood was collected via the forelimb vein at each time point and placed in the presence of EDTA-K2Centrifuging the blood sample at 8000 rpm at 4 deg.C for 6min in an anticoagulant tube to obtain a plasma sample, and freezing the plasma in a refrigerator at-80 deg.C.
Plasma sample analysis
Plasma samples of compound 2 were analyzed by protein precipitation: taking 20 mu L of plasma, adding 200 mu L of internal standard (acetonitrile solution containing 50ng/mL of tolbutamide), vortexing for 10min, then centrifuging for 20min at 4000 rpm, taking 100 mu L of supernatant, adding 100 mu L of water, vortexing and uniformly mixing for 3min, and then carrying out LC-MS/MS analysis.
The experimental results are as follows:
table 8: beagle PK evaluation results (IV)
AUCinfArea 0 → ∞ under curve when drug is represented
CL stands for clearance
VssRepresenting steady state apparent distribution volume
TmaxRepresenting the time to peak of blood concentration
CmaxRepresenting peak plasma concentration
T1/2Represents the half-life
F% represents absolute bioavailability
As can be seen from the experimental results in tables 8 and 9, after the compound is administered in beagle dogs in IV and PO, the results show that the compound of the present invention has good pharmacokinetic properties, higher exposure, longer half-life, and higher bioavailability when orally administered.
The combined-ring ASK1 inhibitor and the application thereof provided by the invention are described in detail above. The principles and embodiments of the present invention are explained herein using specific examples, which are presented only to assist in understanding the method and its central concept. It should be noted that it would be apparent to those skilled in the art that various changes and modifications can be made in the invention without departing from the principles of the invention, and such changes and modifications are intended to be covered by the appended claims.
Claims (17)
1. A compound of formula (I), a pharmaceutically acceptable salt, ester or stereoisomer thereof:
wherein, X, X1、X2、X3、X4、X5Each independently selected from C, CR8Or N;
R1selected from optionally substituted by one or more Q1Substituted C1-10Alkyl radical, C2-10Alkenyl radical, C1-10Alkoxy, 3-to 8-membered cycloalkyl, C2-10Alkynyl, aryl, heteroaryl or heterocyclyl;
each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl, halo C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino, 3-to 8-membered cycloalkyl, 3-to 8-membered heterocyclyl, phenyl, phenoxy, -O-R8、-C(O)-R8、-OC(O)-R8、-C(O)-O-R8、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-R9、-N(R8)-C(O)-N(R8)(R9) or-C (O) -N (R)8)(R9) In which C is1-6Alkyl, 3-8 membered cycloalkyl, 3-8 membered heterocyclyl, phenyl, phenoxy optionally substituted by one or more C1-6Alkyl, 3-8 membered cycloalkyl, C1-6Alkoxy, hydroxy, amino, carboxy or halogen substitution;
or R1And X1In conjunction therewithThe attached N is bonded to form a heterocyclyl, aryl or heteroaryl group, which is optionally substituted with one or more alkyl, hydroxy or halogen;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, hydroxy C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino, C1-6Alkylthio radical, C1-6Alkylcarbonyl group, C1-6Alkoxy radical C1-6Alkyl radical, C1-6Alkylcarbonyloxy, C1-6Alkylsulfonyl radical, C1-6Alkylaminosulfonyl, di (C)1-6Alkyl) aminosulfonyl, C1-6Alkylsulfonylamino or C1-6An alkylsulfonyloxy group;
R3selected from absent, hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, aryl, heteroaryl, cycloalkyl or heterocyclyl;
each Q2Independently selected from C1-6Alkyl, 3-8 membered cycloalkyl, 3-8 membered cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halogen, cyano, nitro, haloC1-6Alkoxy radical, C1-6Alkylamino, oxo, -O-R8、-O-C(O)-R8、-O-C(O)-N(R8)(R9)、-S-R8、-N(R8)(R9)、-S(=O)-R8、-S(=O)2R8、-O-S(=O)2R8、-S(=O)2-N(R8)(R9)、-S(=O)2-OR8、-N(R8)-C(O)-R9、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-N(R8)(R9)、-C(O)-R8、-C(O)-O-R8、-C(O)-N(R8)-R9or-N (R)8)-S(=O)2-R9Wherein said C is1-6Alkyl, 3-8 membered cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally substituted with one or more halogen, hydroxy, amino, cyano, nitro, carboxy, oxo, C1-6Alkyl or-O-R8Substitution;
each R8And R9Each independently selected from hydrogen and C1-6Alkyl, 3-8 membered cycloalkyl, or when R is8And R9When attached to the same N atom, R8And R9Together with the N atom to which they are attached form a 3-12 membered heterocyclic ring;
selected from single bonds or double bonds.
2. The compound of claim 1, a pharmaceutically acceptable salt, ester, or stereoisomer thereof: wherein,
X2、X3、X4、X5at least one is selected from N;
R1selected from optionally substituted by one or more Q1Substituted C1-6Alkyl radical, C2-6Alkenyl radical, C1-6Alkoxy, 3-to 8-membered cycloalkyl, C2-6Alkynyl, 6-12 membered aryl, 5-12 membered heteroaryl or 3-10 membered heterocyclyl;
each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl, halo C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino, 3-to 8-membered cycloalkyl, 3-to 8-membered heterocyclyl, phenyl, phenoxy, -O-R8、-C(O)-R8、-OC(O)-R8、-C(O)-O-R8、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-R9、-N(R8)-C(O)-N(R8)(R9) or-C (O) -N (R)8)(R9);
Or R1And X1Together with the N to which they are attached form a 5-10 membered heterocyclyl, 6-12 membered aryl or 5-10 membered heteroaryl, said 5-10 membered heterocyclyl, 6-12 membered aryl or 5-10 membered heteroaryl being optionally substituted by one or more C1-6Alkyl, hydroxy or halogen substitution;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, hydroxy C1-6Alkoxy radical, C1-6An alkylamino group;
R3selected from absent, hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, 6-to 10-membered aryl, 5-to 12-membered heteroaryl, 3-to 10-membered cycloalkyl or 3-to 10-membered heterocyclyl;
each Q2Independently selected from C1-6Alkyl, 3-8 membered cycloalkyl C1-6Alkyl, 6-14 membered aryl C1-6Alkyl, 5-14 membered heteroaryl C1-6Alkyl, 3-12 membered heterocyclic group C1-6Alkyl, halogen, cyano, nitro, halogeno C1-6Alkoxy, oxo, -O-R8、-O-C(O)-R8、-O-C(O)-N(R8)(R9)、-S-R8、-N(R8)(R9)、-S(=O)-R8、-S(=O)2R8、-O-S(=O)2R8、-S(=O)2-N(R8)(R9)、-S(=O)2-OR8、-N(R8)-C(O)-R9、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-N(R8)(R9)、-C(O)-R8、-C(O)-O-R8、-C(O)-N(R8)-R9or-N (R)8)-S(=O)2-R9Wherein said C is1-6Alkyl, 3-8 membered cycloalkyl, 6-14 membered aryl, 5-14 membered heteroaryl or 3-12 membered heterocyclyl is optionally substituted with one or more halogen, hydroxy, amino, cyano, nitro, carboxy, oxo, C1-6Alkyl or-O-R8And (4) substitution.
3. The compound, pharmaceutically acceptable salt thereof, ester thereof, or stereoisomer thereof according to any one of claims 1 or 2, having a structure represented by general formula (II),
wherein,
X、X1each independently selected from C, CR8Or N;
R1selected from optionally substituted by one or more Q1Substituted C1-6Alkyl radical, C2-6Alkenyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl, 6-10 membered aryl, 5-10 membered heteroaryl or 3-8 membered heterocyclyl;
each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl, halo C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino, 3-to 8-membered cycloalkyl, 3-to 8-membered heterocyclyl, phenyl, phenoxy, -O-R8、-C(O)-R8、-OC(O)-R8、-C(O)-O-R8、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-R9、-N(R8)-C(O)-N(R8)(R9) or-C (O) -N (R)8)(R9);
Or R1And X1Together with the N to which they are attached form a 5-8 membered heterocyclyl, 6-10 membered aryl or 5-8 membered heterocychcAryl, said 5-8 membered heterocyclyl, 6-10 membered aryl or 5-8 membered heteroaryl optionally substituted with one or more C1-6Alkyl, hydroxy or halogen substitution;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, hydroxy C1-6Alkoxy or C1-6An alkylamino group;
R3selected from absent, hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, 6-8 membered aryl, 5-10 membered heteroaryl, 3-8 membered cycloalkyl or 3-8 membered heterocyclyl;
each Q2Independently selected from C1-6Alkyl, 3-8 membered cycloalkyl C1-6Alkyl, 3-8 membered heterocyclic group C1-6Alkyl, halo C1-6Alkoxy, halogen, cyano, nitro, -O-R8、-O-C(O)-R8、-O-C(O)-N(R8)(R9)、-S-R8、-N(R8)(R9)、-S(=O)-R8、-S(=O)2R8、-O-S(=O)2R8、-S(=O)2-N(R8)(R9)、-S(=O)2-OR8、-N(R8)-C(O)-R9、-N(R8)-C(O)-O-R9、-N(R8)-C(O)-N(R8)(R9)、-C(O)-R8、-C(O)-O-R8、-C(O)-N(R8)-R9or-N (R)8)-S(=O)2-R9Wherein said C is1-6Alkyl, 3-8 membered cycloalkyl, 3-8 membered heterocyclyl optionally substituted with one or more halogens,Hydroxy, amino, cyano, nitro, carboxy, oxo, C1-6Alkyl or-O-R8Substitution;
each R8And R9Each independently selected from hydrogen or C1-6An alkyl group;
selected from single bonds or double bonds.
4. The compound, pharmaceutically acceptable salt, ester or stereoisomer thereof according to any one of claims 1-3, having a structure represented by formula (III),
wherein,
R1selected from the group consisting of optionally substituted 1-3Q1Substituted C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl or 3-8 membered heterocyclyl, each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl radical, C1-6Alkoxy radical, C1-6Alkylcarbonyl group, C1-6Alkoxycarbonyl group, C1-6Alkylamido, aminoacyl, C1-6Alkylaminoacyl, di (C)1-6Alkyl) aminoacyl, halo C1-6Alkoxy radical, C1-6Alkylamino radical, di (C)1-6Alkyl) amino or 3-8 membered cycloalkyl; r2、R4、R6、R7Each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, hydroxy C1-6Alkoxy or C1-6An alkylamino group;
R3selected from hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from the group consisting of optionally substituted 1-3Q2Substituted C1-6Alkyl radical, C1-6Alkylamino radical, C1-6Alkoxy, phenyl, 5-8 membered heteroaryl, or 3-6 membered heterocyclyl;
each Q2Independently selected from C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl C1-6Alkyl, 3-6 membered heterocyclic group C1-6Alkyl, halogen, cyano, hydroxy, amino, nitro, haloC1-6Alkoxy radical, C1-6Alkylamino radical, C1-6Alkylcarbonyl group, C1-6Alkylcarbonyloxy, C1-6Alkyl mercapto group, C1-6Alkylsulfonyl radical, C1-6Alkyloxycarbonyl, C1-6Alkylamido radical, C1-6Alkylaminoacyl, C1-6Alkylsulfonylamino, wherein said C1-6The alkyl, 3-6 membered cycloalkyl or 3-6 membered heterocyclyl is further optionally substituted with 1 to 3 halogen, hydroxy, amino, cyano, nitro, carboxy, C1-6Alkyl substitution;
selected from single bonds or double bonds.
5. The compound of any one of claims 1-4, a pharmaceutically acceptable salt, ester, or stereoisomer thereof,
wherein,
R1selected from optionally 1-2Q1Substituted methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, or morpholinyl, each Q1Independently selected from halogen, cyano, hydroxyAmino, nitro, carboxyl, methyl, ethyl, methoxy, ethoxy, propoxy, isopropoxy, methoxycarbonyl, ethoxycarbonyl, methylamino, ethylamino, dimethylamino, diethylamino, aminoacyl, methylaminoacyl, ethylacylo, dimethylaminyl, ethylacylo;
R2、R4、R6、R7each independently selected from hydrogen, fluoro, bromo, chloro, iodo, hydroxy, amino, cyano, nitro, carboxy, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, trifluoromethyl, trifluoroethyl, difluoromethoxy, or trifluoromethoxy;
R3selected from hydrogen, fluoro, bromo, chloro, iodo, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl or formyl;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally 1-2Q2Substituted phenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridyl or pyrimidinyl;
each Q2Independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, methoxy, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, wherein said methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl are further optionally further coated with1-3 halogen, hydroxyl, amino, cyano, nitro, carboxyl, methyl, ethyl, propyl and isopropyl.
6. The compound of any one of claims 1-3, a pharmaceutically acceptable salt, ester, or stereoisomer thereof, having a structure according to formula (IV):
wherein,
R1selected from the group consisting of optionally substituted 1-3Q1Substituted C1-6Alkyl radical, C1-6Alkoxy or 3-6 membered cycloalkyl, each Q1Independently selected from halogen, cyano, hydroxy, amino, nitro, carboxyl, C1-6Alkyl radical, C1-6Alkoxy, aminoacyl, C1-6Alkylaminoacyl, di (C)1-6Alkyl) aminoacyl, C1-6Alkylamino or di (C)1-6Alkyl) amino;
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl or halo C1-6An alkoxy group;
R5selected from the group consisting of optionally substituted 1-3Q2Substituted phenyl or 5-8 membered heteroaryl;
each Q2Independently selected from C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl C1-6Alkyl, 3-6 membered heterocyclyl or 3-6 membered heterocyclyl C1-6Alkyl, wherein the 3-6 membered cycloalkyl or 3-6 membered heterocyclyl is further optionally substituted with 1 to 3 halogens, hydroxy, amino, cyano, nitro, carboxy, C1-6Alkyl substitution.
7. The compound of claim 6, a pharmaceutically acceptable salt, ester, or stereoisomer thereof,
wherein,
R1selected from optionally 1-2Q1Substituted methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, said substituents Q1Selected from the group consisting of halogen, cyano, hydroxy, amino, nitro, carboxy, methyl, ethyl, methoxy, ethoxy, propoxy, isopropoxy, methylamino, ethylamino, dimethylamino, diethylamino, aminoacyl, methylaminoacyl, ethylaminol, dimethylaminyl, diethylaminoacyl; (ii) a
R2、R4、R6、R7Each independently selected from hydrogen, fluoro, bromo, chloro, iodo, hydroxy, amino, cyano, nitro, carboxy, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, tert-butoxy, trifluoromethyl, trifluoroethyl, or trifluoromethoxy;
R5selected from optionally 1-2Q2Substituted phenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolylpyridinyl or pyrimidinyl;
each Q2Independently selected from methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, methoxy, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, wherein said cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl are further optionally substituted with 1-2 halogens, hydroxy, amino, cyano, nitro, carboxy, methyl, ethyl, propyl or isopropyl.
8. The compound of any one of claims 1-3, a pharmaceutically acceptable salt, ester, or stereoisomer thereof, having a structure represented by formula (V):
wherein,
R2、R4、R6、R7each independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxyl and C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl or halo C1-6An alkoxy group;
R3selected from hydrogen, halogen, C1-6Alkyl, halo C1-6Alkyl, hydroxy C1-6Alkyl or C1-6An alkylcarbonyl group;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted phenyl or 5-8 membered heteroaryl;
each Q2Independently selected from C1-6Alkyl radical, C1-6Alkoxy, 3-6 membered cycloalkyl C1-6Alkyl, 3-6 membered heterocyclyl or 3-6 membered heterocyclyl C1-6Alkyl, wherein the 3-6 membered cycloalkyl or 3-6 membered heterocyclyl is further optionally substituted with one or more halo, hydroxy, amino, cyano, nitro, carboxy.
9. The compound of claim 8, a pharmaceutically acceptable salt, ester or stereoisomer thereof,
wherein,
R2、R4、R6、R7each independently selected from hydrogen, fluorine, bromine, chlorine, iodine, hydroxyl, amino, cyano, nitro, carboxyl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, hydroxyl, carboxyl, amino, cyano, amino, cyano, nitro, carboxyl, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy,tert-butoxy, trifluoromethyl, trifluoroethyl, or trifluoromethoxy;
R3selected from hydrogen, fluoro, bromo, chloro, iodo, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl or formyl;
n is selected from 1 or 2, and when n is selected from 2, R3May be the same or different;
R5selected from optionally substituted by one or more Q2Substituted phenyl, furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, tetrazolyl, pyridyl or pyrimidinyl;
each Q2Selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, methoxy, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuryl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, wherein the cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl are further optionally substituted with one or more halogen, hydroxy, amino, cyano, nitro, carboxy, methyl, ethyl, propyl or isopropyl groups.
10. The compound of any one of claims 1-9, a pharmaceutically acceptable salt, ester, or stereoisomer thereof, selected from:
。
11. a process for the preparation of a compound of formula (I), wherein the process comprises:
(1) reacting a compound shown as a general formula (I-1) with a compound shown as a general formula (I-2) to obtain a compound shown as a general formula (I);
or (2) reacting the compound represented by the general formula (I-3) with the compound represented by the general formula (I-2) to obtain a compound represented by the general formula (I-4); the nitro group in the compound shown in the general formula (I-4) is subjected to functional group conversion reaction to obtain a compound shown in the general formula (I);
R1、R2、R3、R4、R5、R6、R7、n、X、X1、X2、X3、X4、X5as defined in any of claims 1 to 10, substituent a is selected from leaving groups, such as halogen.
12. A method for synthesizing a compound of formula (III), wherein the method comprises:
(1) reacting the compound shown in the general formula (III-1) with the compound shown in the general formula (III-2) to obtain a compound shown in the general formula (III);
or (2) reacting the compound shown in the general formula (III-3) with the compound shown in the general formula (III-2) to obtain a compound shown in a general formula (III-4); the nitro group in the compound shown in the general formula (III-4) is subjected to functional group conversion reaction to obtain a compound shown in the general formula (III);
wherein R is1、R2、R3、R4、R5、R6、R7N is as defined in any one of claims 4 to 10, and substituent a is selected from a leaving group, such as halogen.
13. A compound of the formula having the formula:
wherein R is1、R2、R3、R4、R5、R6、R7N is as defined in any one of claims 4 to 10, and substituent a is selected from a leaving group, such as halogen.
14. A pharmaceutical composition comprising a compound of any one of claims 1-10, a pharmaceutically acceptable salt, ester, or stereoisomer thereof, and optionally one or more second therapeutically active agents; preferably, the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers and/or diluents.
15. A pharmaceutical formulation comprising a compound according to any one of claims 1 to 10, a pharmaceutically acceptable salt, ester or stereoisomer thereof and one or more pharmaceutically acceptable carriers and/or diluents; the pharmaceutical preparation is any clinically or pharmaceutically acceptable dosage form, preferably an oral preparation or an injection; more preferably, the pharmaceutical formulation further comprises one or more second therapeutically active agents.
16. Use of a compound of any one of claims 1-10, a pharmaceutically acceptable salt, ester or stereoisomer thereof, or a pharmaceutical composition of claim 14, or a pharmaceutical formulation of claim 15, in the manufacture of a medicament for the treatment and/or prevention of ASK 1-mediated diseases and related disorders.
17. The use of claim 16, said ASK1 mediated and related diseases are selected from cardiovascular diseases including but not limited to pulmonary hypertension, multiple sclerosis, atherosclerosis, angina pectoris, intermittent claudication syndrome, myocardial infarction, heart failure; selected from pulmonary diseases including but not limited to asthma, chronic obstructive pulmonary disease, bronchitis, and emphysema; selected from metabolic disorders including but not limited to diabetes and its complications, metabolic syndrome, dyslipidemia, obesity, glucose intolerance, hypertension, high serum cholesterol and higher triglycerides; hepatobiliary kidney diseases, including but not limited to diabetic nephropathy, non-alcoholic fatty liver disease, bile acid disorders, primary sclerosing cholangitis, cholesterol stones, fatty liver, cirrhosis, hepatitis, liver failure, cholestasis, cholelithiasis; hyperproliferative diseases include, but are not limited to, gastric cancer, liver cancer, polyposis, colon cancer, breast cancer, pancreatic cancer, esophageal cancer; other diseases, including neurodegenerative diseases, fibrosis-related diseases, stroke, inflammatory bowel diseases, autoimmune disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810236048 | 2018-03-21 | ||
CN2018102360480 | 2018-03-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110294742A true CN110294742A (en) | 2019-10-01 |
CN110294742B CN110294742B (en) | 2023-01-31 |
Family
ID=68026243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810790218.XA Active CN110294742B (en) | 2018-03-21 | 2018-07-18 | Fused ring ASK1 inhibitor and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110294742B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109956928A (en) * | 2017-12-14 | 2019-07-02 | 四川科伦博泰生物医药股份有限公司 | Pyridine compounds and their, preparation method and the usage |
CN111018831A (en) * | 2019-11-21 | 2020-04-17 | 中国药科大学 | Apoptosis signal-regulating kinase inhibitor and application thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102985418A (en) * | 2010-07-02 | 2013-03-20 | 吉利德科学股份有限公司 | Apoptosis signal-regulating kinase inhibitors |
NZ597533A (en) * | 2009-07-13 | 2014-03-28 | Gilead Sciences Inc | Apoptosis signal-regulating kinase inhibitors |
CN104080771A (en) * | 2012-01-27 | 2014-10-01 | 吉利德科学公司 | Apoptosis signal-regulating kinase inhibitor |
CN106660994A (en) * | 2014-06-13 | 2017-05-10 | 吉利德科学公司 | Phosphatidylinositol 3-kinase inhibitors |
NZ722945A (en) * | 2012-01-27 | 2018-02-23 | Gilead Sciences Inc | Apoptosis signal-regulating kinase inhibitor |
CN109071498A (en) * | 2017-02-16 | 2018-12-21 | 四川科伦博泰生物医药股份有限公司 | Kinase inhibitor and its preparation method and application |
CN109071448A (en) * | 2017-01-22 | 2018-12-21 | 福建广生堂药业股份有限公司 | Ask1 inhibitor and its preparation method and application |
CN109265443A (en) * | 2017-07-18 | 2019-01-25 | 南京圣和药业股份有限公司 | Heterocyclic compound and its application as ASK inhibitor |
CN109456308A (en) * | 2017-09-06 | 2019-03-12 | 南京圣和药业股份有限公司 | Heterocyclic compound and its application as ASK inhibitor |
CN109956928A (en) * | 2017-12-14 | 2019-07-02 | 四川科伦博泰生物医药股份有限公司 | Pyridine compounds and their, preparation method and the usage |
-
2018
- 2018-07-18 CN CN201810790218.XA patent/CN110294742B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ597533A (en) * | 2009-07-13 | 2014-03-28 | Gilead Sciences Inc | Apoptosis signal-regulating kinase inhibitors |
CN102985418A (en) * | 2010-07-02 | 2013-03-20 | 吉利德科学股份有限公司 | Apoptosis signal-regulating kinase inhibitors |
CN104080771A (en) * | 2012-01-27 | 2014-10-01 | 吉利德科学公司 | Apoptosis signal-regulating kinase inhibitor |
NZ722945A (en) * | 2012-01-27 | 2018-02-23 | Gilead Sciences Inc | Apoptosis signal-regulating kinase inhibitor |
CN106660994A (en) * | 2014-06-13 | 2017-05-10 | 吉利德科学公司 | Phosphatidylinositol 3-kinase inhibitors |
CN109071448A (en) * | 2017-01-22 | 2018-12-21 | 福建广生堂药业股份有限公司 | Ask1 inhibitor and its preparation method and application |
CN109071498A (en) * | 2017-02-16 | 2018-12-21 | 四川科伦博泰生物医药股份有限公司 | Kinase inhibitor and its preparation method and application |
CN109265443A (en) * | 2017-07-18 | 2019-01-25 | 南京圣和药业股份有限公司 | Heterocyclic compound and its application as ASK inhibitor |
CN109456308A (en) * | 2017-09-06 | 2019-03-12 | 南京圣和药业股份有限公司 | Heterocyclic compound and its application as ASK inhibitor |
CN109956928A (en) * | 2017-12-14 | 2019-07-02 | 四川科伦博泰生物医药股份有限公司 | Pyridine compounds and their, preparation method and the usage |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109956928A (en) * | 2017-12-14 | 2019-07-02 | 四川科伦博泰生物医药股份有限公司 | Pyridine compounds and their, preparation method and the usage |
CN111018831A (en) * | 2019-11-21 | 2020-04-17 | 中国药科大学 | Apoptosis signal-regulating kinase inhibitor and application thereof |
CN111018831B (en) * | 2019-11-21 | 2022-05-31 | 中国药科大学 | Apoptosis signal-regulating kinase inhibitor and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN110294742B (en) | 2023-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115504986B (en) | Apoptosis signal regulating kinase inhibitor and preparation method and application thereof | |
KR102426043B1 (en) | Inhibitors of activin receptor-like kinases | |
JP7212693B2 (en) | Bridged Bicyclic Compounds as Farnesoid X Receptor Modulators | |
WO2021073439A1 (en) | Pyrazine derivative for inhibiting shp2 activity | |
CN106220635B (en) | The dihydro diaza * and carbazole ketone at the condensed Fourth Ring or five rings as PARP inhibitor | |
KR20030036922A (en) | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | |
WO2019062733A1 (en) | Pde9 inhibitor and use thereof | |
WO2017071516A1 (en) | Kinase inhibitor, and preparing method and pharmaceutical use thereof | |
CN114423753A (en) | Heterobicyclic amides as CD38 inhibitors | |
CN107207504A (en) | Phthalazinone derivatives, preparation method and the usage | |
WO2022111526A1 (en) | Benzene ring derivative, and composition and pharmaceutical use thereof | |
JP2023538091A (en) | Heterocyclic compounds as BTK inhibitors | |
WO2019076336A1 (en) | Pyrazolyl-containing tricyclic derivative, preparation method therefor and use thereof | |
CN114835687B (en) | AhR inhibitors | |
CN110294742B (en) | Fused ring ASK1 inhibitor and application thereof | |
CN114181208B (en) | Tri-fused ring AhR inhibitor and application thereof | |
CN111170995A (en) | ASK1 inhibitor and application thereof | |
US20110152304A1 (en) | Spiroazaindoles | |
CN112384508B (en) | Tricyclic ASK1 inhibitor and application thereof | |
WO2021197250A1 (en) | Novel compound as rearranged during transfection kinase inhibitor | |
EP3750893B1 (en) | Dioxazoline compound, preparation method therefor, and uses thereof | |
CN115698005B (en) | Fused ring AhR inhibitors | |
CN114181212B (en) | Pyridazinone AhR inhibitors | |
WO2022135390A1 (en) | Ketohexokinase inhibitor and use thereof | |
KR20230096965A (en) | Arylamide compound, pharmaceutical composition containing the same, and preparation method and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |